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The highly aggressive cancer, malignant mesothelioma, responds poorly to
available treatment options. As most individuals diagnosed with these tumors
succumb to the disease within about 2 years of diagnosis, it is imperative to
develop a more thorough understanding of molecular mechanisms of the disease
and thus design more suitable therapeutic options. Neurofibromatosis Type 2
(NF2) is one of the most commonly inactivated tumor suppressor genes in
mesothelioma. The downstream signaling pathways that may be disrupted as a
result of this inactivation are not entirely understood. Conversely, the tumor
suppressor gene that is often referred to as the “Genome Gatekeeper,” TP53, is
rarely inactivated in mesothelioma tumors. As TP53 is mutated in the majority of
human cancers, in those cancers where TP53 is not mutated, its function may be
regulated by other mechanisms. Evidence suggests that NF2 may be upstream
in a signaling cascade of TP53, such that NF2 is responsible for MDM2
degradation. MDM2 is a negative regulator of p53 (the protein product of TP53),
so that loss of NF2 would ultimately result in decreased function of p53.
The hypothesis of this study is that inactivation of NF2 plays a critical role in
cellular growth dysregulation through altering normal regulation of MDM2 and
thus p53 levels. To test this hypothesis, the role of the NF2 gene in regulating
p53 function and cellular growth in “normal” mesothelial cells and in a
mesothelioma cell culture model were assessed. Normal function of NF2 was
restored by transfection of a wild-type NF2 construct in a mesothelioma cell
culture model. Additionally, NF2 expression was reduced in “normal” mesothelial
cells by shRNA knockdown. In both in vitro models, alterations in NF2
expression resulted in significant changes in cell cycle mechanisms, including
proliferative, apoptotic, and cell cycle arrest. These events were linked to
aberrant p53 function. Finally, an in vivo mouse model was used to determine
the role Nf2 in the development of pleural mesothelioma following asbestos
exposure. A better understanding of the molecular mechanisms that are
disrupted following NF2 inactivation will help with design of more effective
therapeutic strategies.
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INTRODUCTION

Cell Cycle Control and Cancer
Tumor development is typified by a multitude of cellular changes including
the loss of normal cell growth control, formation of new blood vessels, and
acquisition of the ability to metastasize and invade foreign tissues, (Rous and
Friedewald 1941; Armitage and Doll 1954; Hanahan and Weinberg 2000;
Vermeulen et al. 2003a). Thought to arise from a single cell, cancer results from
mutations and aberrations in the genetic code that accumulate over time, as this
cell passes acquired mutations onto daughter cells (Tsuda et al. 1988; Sugimura
et al. 1992). These mutations can be somatic or germline, but those that alter the
function of key cell cycle regulators, such as proto-oncogenes or tumor
suppressor genes (TSGs), can be critical for the eventual development of
neoplasms (Shackelford et al. 1999; Evan and Vousden 2001; Croce 2008). The
type and number of mutations that an individual will sustain in a lifetime is directly
related to endogenous factors such as genetic predisposition and exogenous
factors such as exposure to carcinogens. (Figure 1) (Sugimura et al. 1992;
Minamoto et al. 1999).
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FIGURE 1

(Minamoto et al. 1999)
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Figure 1. Environmental and endogenous factors can result in tumor
development over time.

Cancer most often develops over long periods of time, with both endogenous and
environmental factors contributing to disease formation. Germline mutations,
such as those that affect TSGs or oncogenes, coupled with somatic mutations
induced by environmental factors, can ultimately result in cell transformation.
Another method of TSG inactivation is methylation of CpG islands in the
promoter region of critical genes, which results in transcriptional silencing of the
TSG. Also, in addition to germline mutations that create an increased risk to
individuals for cancer susceptibility, polymorphisms in metabolic susceptibility
genes create an increased cancer risk. For example, genetic variability in genes
related to phase I and phase II detoxification enzymes, such that lower levels of
exposure to toxicants, will cause adverse health events as the toxicant is not
readily cleared from the body.
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Both tumor suppressor genes and proto-oncogenes are largely involved in
the regulation of cell growth. In a normal cell, proto-oncogenes act to stimulate
proliferation on a controlled basis (Vermeulen et al. 2003b; Croce 2008;
Johansson and Persson 2008). On the other hand, TSGs act at cell-cycle
checkpoints to inhibit cell cycle progression until conditions are right for cellular
division to take place. Most of these checkpoints occur at the G1 to S phase
transition of the cell cycle, but the checkpoints can also occur in S phase, at the
G2 to M phase transition, or during mitosis (Figure 2) (Shackelford et al. 1999;
Tachibana et al. 2005; Johansson and Persson 2008). Mutations in protooncogenes, which after activation are called oncogenes, result in continued
stimulation of growth. In a similar manner, inactivation of TSGs can result in the
dysregulation of normal cell cycle mechanisms, allowing for progression into S
phase when this transition would normally be prevented. Thus, the accumulation
of changes that alter the expression level of these key genes can eventually
result in tumor initiation through continual cell cycle progression (Shackelford et
al. 1999; Hanahan and Weinberg 2000; Evan and Vousden 2001).
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FIGURE 2

(Tachibana et al. 2005)
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Figure 2. A Diagram of the Cell Cycle.

The cell cycle consists of gap 1 phase (G1 phase), gap 0 (G0), S phase, gap 2
(G2), and mitosis (M phase). During G1 , a cell prepares for DNA replication,
which occurs during S phase. Following S phase, cells transition into G2 phase
while preparing for mitosis. Cells can exit the cell cycle during G1 into G0, a
quiescent or resting state where cells are still metabolically active but are not
actively cycling.
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In most cases TSGs act in response to regulatory cues, often caused by
cellular stress, to halt cell cycle progression. For example, depending on the
type of DNA damage, the major TSG TP53 is a transcription factor for hundreds
of genes, initiating responses such as cell cycle arrest, apoptosis, and DNA
repair mechanisms (Lane 1992; Rotter et al. 1994; Levine 1997; Gottlieb and
Oren 1998; May and May 1999; Oren 1999). Other TSGs might not directly
interact with cell cycle checkpoints, but instead function to protect and aid in the
activity of other TSGs. Such is the case for p14/ARF, which is activated following
DNA damaging events to inhibit MDM2 and prevent downstream p53
degradation (Chin et al. 1998; Zhang et al. 1998; Vermeulen et al. 2003b). In
fact, this type of p53 deregulation is one of the possible mechanisms that may be
disrupted in malignant pleural mesothelioma (MPM) contributing to loss of
cellular growth control. TP53 is rarely found mutated in this type of cancer,
whereas inactivating mutations are often found in other TSGs that may protect
activity of p53 (Lecomte et al. 2005).

Malignant Mesotheliomas
Malignant mesothelioma is an aggressive tumor that is strongly associated
with exposure to asbestos fibers (Wagner et al. 1960). The overall incidence of
these tumors is relatively rare. Individuals with these locally aggressive tumors
are given a poor prognosis with a survival time of less than 2 years (Rusch 1995;
Murthy and Testa 1999; Altomare et al. 2005; Jaurand and Fleury-Feith 2005;
Lecomte et al. 2005; Tan and Treasure 2005). Noting the world-wide problem,
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Treasure and Sedrakyan (2004) reported on the risk to workers in the UK, “One
in every hundred men born in the 1940s will die of malignant pleural
mesothelioma…In the developing world alone 100,000 people alive now will die
from it.” In the United States, approximately 2,000 to 3,000 new cases of
mesothelioma are being reported annually, and this number is expected to peak
in 2015 (Murthy and Testa 1999; Hodgson et al. 2005). A latency period of 20-40
years occurs between asbestos exposure and disease diagnosis, during which
time there is an accumulation of mutations (Rusch 1995; Jaurand and FleuryFeith 2005; Kumar and Kratzke 2005). It is essential to understand the molecular
mechanisms that are altered during this time to not only design more effective
therapeutics, but also to improve early detection of this neoplasm.
Malignant mesotheliomas are solid tumors that arise from the
mesothelium (Rusch 1995; Altomare et al. 2005; Xiao et al. 2005). The
mesothelium was first described in 1827, and was reported as a single layer of
flat cells that line the surfaces of certain body cavities (Whitaker et al. 1982).
Body cavities where mesothelioma tumors can arise include the pleural, the
peritoneal, pericardial, tunica vaginalis testis, and the ovarian epithelium, with the
most common occurrence of mesothelioma cases occurring in the pleural space
surrounding the lung (Tan and Treasure 2005).
The flat cells described in 1827 were later termed mesothelial cells and in
the pleural space are found to overlie a basement membrane followed by a layer
of connective tissue containing fibroblast-like cells, blood vessels, and lymphatics
(Sahn 1998; Mutsaers et al. 2000; Mutsaers 2002). Mesothelial cells respond to
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pleural injury, synthesizing and secreting inflammatory mediators to protect
against physical damage and invasive organisms (Figure 3) (Jaurand and FleuryFeith 2005). This protective barrier is formed as mesothelial cells align with tight
junctions and are shielded by a “coat” predominantly composed of hyaluronan
(Mutsaers 2004).

9

FIGURE 3

(Mutsaers 2004)
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Figure 3. Mesothelial cell function.

Mesothelial cells form tight junctions and have a hyaluronic coat, which may help
to provide a protective barrier against fibers and invading pathogens. In addition,
these tight junctions trap fluid between the two layers of mesothelial cells,
reducing friction between the two layers of the spaces that they coat allowing for
more effective movement.
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Mesothelial cells line the visceral and parietal surfaces of the cavities that
they encompass, where they act at the border of apposing tissues to reduce
friction allowing for more effective movement (Robinson et al. 2005). Thus, the
visceral and parietal surfaces create the pleural space, which helps the lungs to
move smoothly during breathing. Phenotypic and genetic alterations that occur
in mesothelial cells result in aberrant cell cycle control, leading to uncontrolled
cell growth and resistance to cell death, as well as irregular cell:cell and
cell:matrix interactions, ultimately resulting in MPM (Jaurand and Fleury-Feith
2005).
MPM is most often associated with prior asbestos exposure. With a long
latency period of 20 to 40 years even after exposure has stopped, development
of MPM continues to progress over a long period of time. At the time of
diagnosis, patients typically present with symptoms such as dyspnea (shortness
of breath), difficulty sleeping, cough, chest pain, weight loss, and pleural effusion
(Dunitz 2002; Robinson et al. 2005). The rare number of MPM patients that are
diagnosed early (during Stage 1a) have a much better prognosis, with a median
survival time of more than 5 years (Carbone et al. 2007). However, diagnosis is
problematic and may take 2-3 months (Dunitz 2002; Tan and Treasure 2005).
Diagnosis of a suspected MPM usually involves an investigation into the
occupational and environmental (residential) history. This is followed by a chest
x-ray, which may show signs of pleural effusion, pleural thickening, pleural
plaques, or asbestosis, all conditions that can be related to prior asbestos
exposure. One factor complicating MPM diagnosis is that MPM is commonly
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misdiagnosed as adenocarcinoma, as both of these diseases often present with
multiple tan nodules in a thickened pleura. Distinction must be made between
the two before treatment can begin (Robinson et al. 2005). Final diagnosis
usually requires thoracocentesis and/or biopsy for cytological and histological
analysis, utilizing a large panel of histological markers specific for mesothelioma
or aimed at ruling out other suspected malignancies (Dunitz 2002; Robinson et
al. 2005).
Adding to the complexity, there are three main histological subtypes of
malignant pleural mesotheliomas (MPM). These include epithelioid (accounts for
about 60%), sarcomatoid (~30%), and biphasic (~ 10%) (Dunitz 2002). The
modifications that take place during mesothelial cell hyperplasia that result in
these different cellular subtypes are not clear (Jaurand and Fleury-Feith 2005).
However, distinguishing between these different subtypes may be a useful tool to
determine the type of treatment that will best suit the patient (Dunitz 2002).
Most patients are diagnosed during a more advanced stage at which point
this normally slow growing tumor becomes much more aggressive, progressing
rapidly to an untreatable state (Dunitz 2002; Tan and Treasure 2005). Treatment
at this stage becomes more for relief of symptoms, and most patients of this
stage succumb to the disease within 4-24 months (Rusch 1995; Murthy and
Testa 1999; Jaurand and Fleury-Feith 2005; Lecomte et al. 2005; Tan and
Treasure 2005). Advances have been made in regards to treatment strategies in
recent years, improving patient outcomes.
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One therapeutic strategy is surgical resection of the tumor, involving
extrapleural pneumonectomy to remove gross tumor regions followed by
adjuvant therapies, typically radiotherapy, to kill any remaining cancerous tissue.
However, this treatment is suitable for only certain cases of mesothelioma
patients. Chemotherapeutic options for mesothelioma are currently not
considered to be curative, but are used more for a palliative line of defense.
(Robinson et al. 2005; Tan and Treasure 2005). Finally, a number of recent
clinical trials using gene therapy have shown some promise in mesothelioma
treatment. Because of their location and relative accessibility, mesothelioma
tumors are considered to be a good tumor type for gene therapeutic options, as
this therapy can be directly injected into the tumor to target the tumor cells. The
challenge involved with this type of therapy is improving vector delivery systems
to target tumor cells and also determining which genes, or types of genes, will
serve to be most effective (van der Most et al. 2006).
Genomic analysis of mesotheliomas has revealed a series of related subchromosomal deleted regions and alterations, some of which are involved in loss
of cell cycle regulation. Within these regions affected, TSGs are the type of
genes most commonly affected. Included in these are p16/INK4a and p14/ARF
on 9p, and NF2 on 22q (Figure 4) (Jaurand and Fleury-Feith 2005; Musti et al.
2006; Andujar et al. 2007). Missing from the list of frequently mutated genes are
TP53 and RB, which is interesting as these genes are frequently found mutated
in other types of human cancers (Toyooka et al. 2008).
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FIGURE 4
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Figure 4. Model of mesothelioma genomic alterations.

This model is based on incidences of inactivating mutations in specific genes and
genomic deletions found in human mesotheliomas. Commonly inactivated genes
include p16, p14, and NF2. Interestingly, both RB and p53 are rarely inactivated
by mutation in malignant mesotheliomas. The model also includes SV40
interactions with p53, a known virus-gene interaction. While asbestos is
considered the leading cause of mesothelioma tumor development, SV40 is also
implicated in disease development.
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A number of studies have been conducted focusing on the molecular
mechanisms altered in relationship to the loss of genes that function upstream of
these genes, in particular with regards to the effect that the loss of both
p16/INK4a and p14/ARF might have on p53 and RB function, respectively
(Lecomte et al. 2005). While there are known mechanisms whereby p16/INK4a
and p14/ARF are involved with the regulation of p53 and RB, the role for NF2 in
regulation of these pathways has not been looked into as extensively. Most of
the research into the role of NF2 loss in mesothelioma tumors have focused on
other pathways that the gene may be involved, but few have focused on
mechanisms whereby it may interact with p53 or RB (Jung et al. 2005). The role
of merlin in the regulation of these TSGs may be indirect, relaying extracellular
growth signals to these downstream genes (Tsukita et al. 1994; Shaw et al.
1998b; McClatchey and Giovannini 2005).
Environmental exposures are thought to play a large role in the
development of MPM tumors, with exposure to simian virus 40 (SV40), erionite,
and asbestos fibers being implicated as possible causes (Carbone et al. 1999;
Testa and Giordano 2001; Dogan et al. 2006; Carbone et al. 2007). Infection
with SV40 has been linked to mesothelioma, brain tumors, non-Hodgkin’s
lymphoma, and osteosarcoma (Khalili et al. 2008). SV40 binds to and inhibits
TSGs, in particular the major TSGs p53 and Rb. Many people were exposed to
this oncogenic virus in the 1950s to1960s as it was a contaminant of some forms
of polio vaccine (Shah 2006). The role of SV40 in mesothelioma development
remains controversial, as many mesothelioma tumors are negative for SV40
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infection (Aoe et al. 2006). More robust detection systems for the virus need to
be developed to determine its role in carcinogenesis (Pershouse et al. 2006;
Shah 2006). Erionite belongs to the zeolite group of minerals, and is considered
the world’s most carcinogenic mineral according to the World Health
Organization (WHO), with a potency 200-1000 times greater than asbestos
minerals (Carbone et al. 2002; Dogan et al. 2008). People in the Cappadocia
region of Turkey were found to have a high rate of malignant mesothelioma,
which was linked to erionite exposure (Dogan et al. 2006; Carbone et al. 2007).
The leading cause of mesothelioma, however, is asbestos, with 80% of
individuals diagnosed with the disease having had a prior documented asbestos
exposure (Jaurand and Fleury-Feith 2005).

Asbestos
Asbestos is the name given to a group of fibrous silicate minerals. There
are two main types of this fibrous minerals, chrysotile asbestos belongs to the
serpentine family of minerals and the amphibole group, which is made up of
crocidolite, tremolite, amosite, actinolite, and anthophyllite (ATSDR ; LaDou
2004). Both types of asbestos are naturally occurring in our environment,
typically occurring as fiber bundles that consist of thin, separable fibers with a
crystalline form. All six types of asbestos are considered hazardous to human
health, with the general grouping of asbestos classified as a carcinogen (Gunter
1994; Lee et al. 2008).
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The term “asbestos” is of Greek origin, meaning “unquenchable” or
“inextinguishable.” These fibers were so named as they share properties of
resistance to heat, chemical, and biological degradation. Virtually indestructible,
asbestos has been used for centuries, dating as far back to 2000-4000 BC where
it was used for the embalming of Egyptian Pharaohs (Tan and Treasure 2005).
In the early 1870s, the mining of asbestos for commercial products began on a
large scale, coinciding with the industrial revolution (Cugell and Kamp 2004).
The flexible, fibrous shape, high tensile strength, inability to conduct electricity,
thermal stability, resistance to chemical degradation, and high absorbency made
asbestos a sought after element for use in commercial products (Ross et al.
2008). In fact, over 3,000 different asbestos-containing products exist, with 85%
of these used in asbestos-cement construction products (LaDou 2004).
However, some of these same properties that made asbestos so desirable for
industrial use are also the same properties that contribute to its toxicity to human
health.
Dormant and undisturbed, asbestos is relatively harmless. When the
fibers separate and become airborne they can be easily inhaled. Once inhaled or
swallowed, most fibers will be expelled from the body through mucous coating
and cough, but those that become lodged in the lung, or elsewhere in the body,
cause eventual health effects (ATSDR ; Miserocchi et al. 2008; Weiner and
Neragi-Miandoab 2009). Dr J.C. Wagner first demonstrated a relationship
between asbestos exposure and the development of mesotheliomas in 1960,
postulating that the increase in mesothelioma in South Africa was linked to the
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mining of crocidolite fibers (Wagner et al. 1960). Shortly after this discovery,
reports of mesothelioma occurrences in the shipbuilding industry following WWII
were linked with asbestos exposures (Sheers and Coles 1980). Since these first
reports, an accumulating amount of evidence has followed linking the fibers to
other asbestos-related diseases (ARDs), including pleural plaques, asbestosis,
and lung cancer (ATSDR ; Sahn 1998).
The mechanism by which asbestos causes mesothelioma is not
completely understood. One suggested mechanism is that asbestos generates
an immune reaction, resulting in macrophage activation and asbestos
phagocytosis. This results in a TNF-α mediated response in mesothelial cells,
activating the NF-κB pathway, allowing mesothelial cells to be resistant to
asbestos-induced apoptosis (Yang et al. 2008). A second method is through the
generation of asbestos-induced reactive oxygen species, interfering with
mesothelial cell homeostasis resulting in hyperplasia. A third suggestion is
actual interference with mitosis, where asbestos might sever the mitotic spindle,
resulting in aneuploidy and chromosomal alterations in daughter cells (Knudsen
et al. 1989). Finally, constant irritation from fibers that become lodged in the
pleural space can cause a continual damage/repair response from the
mesothelial cells, leading to eventual uncontrolled cell growth (Figure 5)
(Robinson et al. 2005; Weiner and Neragi-Miandoab 2009).
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FIGURE 5
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Figure 5. Suggested mechanisms for mesothelial cell tumorigenesis.

Mesothelial cell transformation following asbestos exposure is not completely
understood. It could be that asbestos generates an immune reaction, resulting in
macrophage activation and asbestos phagocytosis. This triggers in a TNF-α
mediated response in mesothelial cells, activating the NF-κB pathway, allowing
mesothelial cells to be resistant to asbestos-induced apoptosis. Another
possibility is through the generation of asbestos-induced reactive oxygen
species, interfering with mesothelial cell homeostasis resulting in hyperplasia. A
third suggested mechanism is that asbestos might sever the mitotic spindle,
resulting in aneuploidy and chromosomal alterations in daughter cells. Finally,
fibers that become lodged in the pleural space can cause constant irritation,
resulting in a continual damage/repair response from the mesothelial cells,
leading to eventual uncontrolled cell growth.
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Although asbestos use has been banned in many developed countries, it
is not yet banned in all countries, including the United States. Considering that
95% of the asbestos mined and used today is chrysotile asbestos, this suggests
that we are “safe.” However, there is debate as to which asbestos fiber-types are
the culprits for ARD manifestations. The majority of studies suggest that the
amphiboles, namely crocidolite, are the cause of ARDs (Mossman 1993;
Mossman et al. 1996; Cugell and Kamp 2004; Schneider et al. 2008). Some of
these studies argue that chrysotile is relatively harmless as it can be easily
cleared from the body. In contrast, numerous studies have shown that chrysotile
is the more harmful fiber, with some groups indicating that it is even more toxic
than the amphibole fibers (McDonald and Fry 1982; Churg et al. 1984;
Huncharek 1987; Dunnigan 1988; Langer and Nolan 1989). Considering that
many times these fibers are found mixed together, confounding the analysis, or
that many of the studies involved a conflict of interest, it is difficult to draw
conclusions as to which fibers are more prone to cause disease (Powers and
Carbone 2002; Yang et al. 2008; Weiner and Neragi-Miandoab 2009).
As asbestos is the leading cause of MPM, it seems promising that its use
and production have decreased over the last decade. However, in many
developing countries asbestos use is not declining and will continue to create
health problems in the future (Joshi and Gupta 2004). In addition, although some
countries have banned the use of asbestos, they have not banned the production
of the mineral for export as a commodity (Table 1) (Keith and Brophy 2004).
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TABLE 1. Asbestos use in metric tons in 2003.
Region and Country Production Imports
Africa
Algeria
10,756
South Africa
6,218
1,470
Zimbabwe
147,000
1
Other
7,386
Total
153,218
21,944
Asia and the Middle East
China
350,000
145,425
India
19,000
175,581
Iran
75,852
Thailand
133,110
Turkey
13,552
Other
159,120
Total
369,000
702,640
Central and North America
Canada
194,350
205
Cuba
9,896
Mexico
20,105
United States
4,634
Other
3,756
Total
194,350
38,596
Europe
Kazakhstan
354,500
3,340
Russia
878,000
1,050
Ukraine
156,393
Uzbekistan
42,362
Other
55,464
Total 1,232,500
258,609
South America
Brazil
194,350
28,395
Colombia
5,000
8,118
Other
4,573
Total
199,516
41,086
Other
3,630
Grand Total
2,148,584
1,066,566

Exports

Apparent
Consumption

4,192
99,262
377
103,831

10,756
3,496
5,000^
9,158
28,642

3,472
2,548
12
127
42
6,307

491,954
192,033
75,840
132,983
13,510
159,013
1,065,333

174,774
20
3,548*
178,342

19,781
9,896
20,085
4,634#
3,756
58,152

18,349
450,031
165,802
634,182

173,891
429,020
156,393
42,362
55,261
856,927

144,343
144,343
1,067,006

78,403
13,118
4,739
96,260
3,629
2,108,943

^ The calculated apparent consumption probably includes about 42, 739 tons going into stocks
and 5,000 tons of estimated consumption.
* Includes exports and re-exports of asbestos fiber.
# The apparent consumption is assumed to equal the imports.

(Adapted from the USGS 2003 Worldwide Asbestos Supply and Consumption
Trend from 1900 through 2003 report)
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According to Table 1, the total worldwide consumption of asbestos in 2003
was more than 2,000,000 tons. Because of this massive level of use, although
these numbers have decreased from the peak of 4,360,000 tons used in the
1975 to 1977 time frame, the incidences of mesothelioma and other ARDs are
going to continue to impact global health (Virta 2005). In fact, by 2020 it is
predicted that the death rate from ARDs will be more than 5,000 deaths per year
in the United Kingdom; the United States already exceeds that number with
possibly more than 10,000 deaths per year attributed to ARDs. In Western
Europe, an ARD epidemic is expected to take the lives of about 500,000 people
before 2035 (Tweedale 2002). The best that we can do until the use of asbestos
has stopped is continue to develop a better understanding of diseases
manifestations that will result from exposure to the fibrous minerals, allowing for
the design of more effective therapeutics.

Neurofibromatosis Type 2 (NF2)
Neurofibromatosis (NF) is a term used to describe two autosomal
dominant disorders resulting in tumors of the central nervous system, NF1 and
NF2 (Trofatter et al. 1993). Originally thought to be related diseases primarily
because of a few clinical similarities (such as nerve sheath neoplasms) seen in
patients of the two syndromes, it was later realized that these diseases are in fact
distinct (Yohay 2006a). Both chromosomal location and the protein products of
these two TSGs verified this fact (Trofatter et al. 1993; Gutmann 1997). The NF1
gene is located on chromosome 17q11.2, and encodes a GTPase-activating

25

protein termed neurofibromin. The main function of neurofibromin as a TSG is
thought to be inhibition of the proto-oncogene Ras. NF2, located on
chromosome 22q12.2, encodes the 595 amino acid protein most commonly
known as merlin. The exact mechanisms whereby merlin controls cell growth are
not completely understood, but this protein does represent a new class of TSGs
as it is thought to mediate cues from the cell membrane linking them to the
cytoskeleton (Trofatter et al. 1993; Yohay 2006a).
Discovered in 1993, mutations in NF2 are commonly associated with
central nervous system tumors, including schwannomas of the eighth cranial
nerve, meningiomas, and ependymomas (Rouleau et al. 1993; Trofatter et al.
1993; Baser et al. 2002; Johnson et al. 2002; Sun et al. 2002). In contrast to
these normally benign tumors, NF2 is also found inactivated by homozygous
deletion mutations or loss of heterozygosity at a high frequency in malignant
mesothelioma tumors (Martuza and Eldridge 1988; McClatchey 2003).
Increasing evidence has shown that merlin contributes to tumor progression in
many cancer types, including hepatocellular carcinoma and thyroid cancers,
suggesting that the role of NF2 in cell cycle control is more complex and broad
than originally thought. As it turns out, merlin differs from the more typical TSGs
in that it lacks a DNA-binding domain, instead sharing a more similar protein
structure to the cytoskeleton-associated proteins and is thus considered to be a
novel type of TSG (McClatchey and Giovannini 2005; Okada et al. 2007; Cole et
al. 2008).
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Merlin belongs to the Protein 4.1 superfamily of proteins, which have a
large role in stabilization of the cellular membrane, as the members are largely
involved in regulatory functions at the cell cortex. The Protein 4.1 superfamily
contains over 40 members divided into five subgroups, all of which share a
conserved FERM domain (four.1 protein, ezrin, radixin, moesin) (Sun et al.
2002). Merlin is most closely related to the ERM subgroup (comprised of ezrin,
radixin, and moesin), with the similarity of sharing 3 functional domains
(Gutmann 1997; Yohay 2006b). These domains include a carboxy-terminal
domain, an α-helical domain, and the FERM domain located in the N-terminal
region of the protein. Although the C-terminal domain is more distantly related,
merlin shares 63% homology to the clover-leafed FERM domain of the ERMs,
and for this reason, the name “merlin” arose from the members of this group:
moesin-ezrin-radixin-like protein (Trofatter et al. 1993; Gautreau et al. 2002).
The sequence similarities shared between merlin and the ERMs suggests that
ability of merlin to regulate cell growth may be by functioning in a similar manner
as the ERMs (Gutmann 1997).
The ERMs are thought to be linkers between the membrane and the
cortical actin cytoskeleton (Cole et al. 2008). Merlin and the ERMs form
intramolecular and intermolecular loops through interactions between the FERM
and C-terminal domains. Differential function of the ERMs is dependent upon
their phosphorylation status, creating secondary structures of the proteins to
cycle between a closed and an open loop form. Hypo-phosphorylated ERMs
result in a closed conformation, and are thought to be inactive. Phosphorylation
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results in ERM activation, and has been shown to control cell morphology,
adhesion, and motility, as well as the transduction of growth signals for both cell
proliferation and cell survival (Gautreau et al. 2002; Sun et al. 2002). Like the
ERMs, many groups have suggested that merlin is also conformationally
regulated (McClatchey and Giovannini 2005; Yohay 2006b). In contrast to the
ERMs, it is the hypo-phosphorylated, closed form of merlin that is considered
active, as dephosphorylation of the protein results in membrane localization and
suppression of cell growth (McClatchey 2003).
As the ERMs and merlin have been shown to share binding partners and
even have been shown to interact with each other heterotypically, functional
overlap is thought to occur between the proteins (McClatchey 2003). With this in
mind, merlin membrane-cytoskeleton interactions have been linked to contact
inhibition of growth in many different cell types (Morrison et al. 2001; Shaw et al.
2001; Lallemand et al. 2003; Curto et al. 2007; Cole et al. 2008). Although merlin
and the ERMs do have some functional overlap, merlin does have many
properties that are distinct from the ERMs. The only member of the ERM family
that is considered a TSG, inactivation of merlin not only results in loss of cell:cell
contact inhibition of growth, it is also suggested to have an effect on cell
proliferation, oncogenic-induced transformation, and apoptotic response (Sainio
et al. 1997; Gutmann et al. 1999; Morrison et al. 2001; Shaw et al. 2001;
Sherman and Gutmann 2001; Lallemand et al. 2003; McClatchey and Giovannini
2005; Xiao et al. 2005; Curto and McClatchey 2008). Each of these phenotypic
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changes are examples of loss of cell cycle control and can ultimately lead to a
tumor formation.
Merlin is activated in vitro by dephosphorylation during conditions such as
high cell density, serum deprivation, or addition of hyaluronic acid, causing
localization to the cell membrane (Shaw et al. 1998b; Okada et al. 2007). At the
cell membrane, merlin reportedly interacts with a number of proteins that have
roles in growth factor receptor signaling, which could provide insight into the role
of merlin in signal trafficking to control cell growth (McClatchey and Giovannini
2005).
At the membrane, merlin interactions include localization to adherens
junctions and cell membrane receptors, such as CD44, to inhibit cell growth
(Sherman et al. 1997; Shaw et al. 1998a; Shaw et al. 1998b; Cole et al. 2008;
Curto and McClatchey 2008). Adherens junctions belong to the cadheren family,
and form between interacting plasma membranes, prototypically of epithelial
cells, creating a link between the cells through actin bundles (Alberts et al. 2002).
CD44 and merlin may function together to inhibit growth as intracellular distance
increases. Hyaluronic acid signaling through CD44 may induce changes in the
phosphorylation status of merlin, thus affecting merlin activity (Morrison et al.
2001). Other possible roles for NF2 in maintaining normal cellular growth may be
through many possible signal transduction mechanisms, including interactions
with Rac/PAK signaling, Cyclin D1, and Mouse Double Minute 2 (MDM2) (Tsukita
et al. 1994; Sainio et al. 1997; Morrison et al. 2001). Because of the vast majority
of cellular processes that are affected by the loss of function of this gene in
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various cell types, it seems reasonable to suggest that under pathological
conditions its inactivation could result in loss of cell cycle control, ultimately
leading to tumor formation (Figure 6).
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FIGURE 6

(McClatchey 2003)
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Figure 6. Merlin localization and potential role in cancer.

Merlin localization to adherens junctions and cell:cell boundaries suggests that
loss of the protein can contribute to cancer formation through loss of cell:cell
communication. In addition, inactivation of the TSG, NF2, can contribute to
metastatic potential through a decreased response to contact inhibition of growth
and thus increased cell motility.
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Localized to the cell membrane after activation, NF2 may act upstream of
p53 by helping to maintain function of the gene under normal growth conditions.
Kim et al. (2004) showed that NF2 played a role in MDM2 degradation in mouse
fibroblast 3T3 cells. Involved in an autoregulatory feedback loop with p53,
MDM2 is responsible for degradation of the genome gatekeeper, so increases in
expression of the MDM2 protein could be detrimental to p53 stability. If merlin is
involved in MDM2 degradation in other cells types, loss of NF2 could contribute
to an increase in MDM2 and thus increased p53 degradation, thereby a
diminished ability of p53 to function following DNA stress.

TP53
The role of the transcription factor p53 in cancer development has been
widely characterized. Considered the “Guardian of the Genome,” p53 plays a
key role in maintaining genomic integrity by serving as a cell-cycle checkpoint
(Lane 1992; Levine 1997). Under normal cellular growth conditions, p53 is kept
at low-steady state levels. In response to stress, p53 is activated and acts as a
transcription factor for many downstream targets, and is capable of initiating
several protective pathways. UV radiation, hypoxic conditions, and
overexpression of oncogenes are examples of cellular stressors that are capable
of inducing p53 activity (Vogelstein et al. 2000). Depending on the type of stress,
p53 is activated through mechanisms like phosphorylation or acetylation, and it is
rapidly stabilized to activate downstream targets. These pathways include, but
are not limited to the induction of cell-cycle arrest, DNA repair mechanisms, and
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apoptosis (Gottlieb and Oren 1998; Vogelstein and Kinzler 2004; Poon et al.
2007). For example, p53 initiates cell cycle arrest following DNA damage
through the upregulation of p21, a member of the CDK family of cell cycle
inhibitors known as an early cell cycle response molecule (Toledo and Wahl
2006). When damage is severe, p53 is a direct transcription factor for the proapoptotic member of the Bcl-2 family member, Bax (Miyashita and Reed 1995;
Gottlieb and Oren 1998; Kelekar and Thompson 1998). Thus, loss of p53 either
through mutation or inactivation through other means can be critical for the
developing cancer cell.
While TP53 is mutated in ~50% of human cancers, in those cancers
where the p53 gene is not directly mutated other mechanisms might contribute to
aberrant p53 function. For example, the large T-antigen of the SV40 virus is
thought to bind to both p53 and RB, inhibiting the ability of the TSGs to respond
properly to DNA stress signals (Ludlow 1993; Pershouse et al. 2006; Khalili et al.
2008). Another method of wild-type p53 instability might be through the loss of
other TSGs that act upstream of the gatekeeper helping to maintain its function
(Chin et al. 1998; Pomerantz et al. 1998; Zhang et al. 1998; Oren 1999). Under
normal conditions for cell growth, p53 levels are largely controlled through
interactions with MDM2 (Brooks and Gu 2006). Following cellular stress, p53 is
activated and stabilized, thereby disrupting the ability of MDM2 to bind to the
protein. If protein levels are not controlled, p53 over-activity in normal cells can
result in cell death. This is apparent in MDM2-deficient mice which are
embryonic lethal, whereas inactivation of both MDM2 and p53 to produce double
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null mice rescues this effect (Joseph and Moll 2003). Thus, to control its own
activity, p53 forms an auto-regulatory feedback loop with MDM2, acting as a
direct transcription factor for the ubiquitin ligase, which in turn attaches ubiquitin
molecules to p53 stimulating its degradation by the proteasome (Figure 7).
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FIGURE 7
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Figure 7. Example of p53 function and autoregulation following DNA
damage.

After a DNA damaging event, p53 is activated to induce activities like cell-cycle
arrest through the induction of p21, or if damage is more severe, p53 will activate
apoptosis through the transcription of the pro-apoptotic Bcl2 family member, Bax.
When p53 has carried out its protective role, it acts as a transcription factor for
MDM2, which ubiquitinates the protein tagging it for proteosome degradation.
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Besides inactivation by mutation, another method for decreased p53
function could be through oncogene activation that negatively regulates p53,
such as can happen with MDM2. Because of the ability of the E3 ubiquitin ligase
MDM2 to negatively regulate p53, MDM2 is sometimes considered to have
oncogenic properties and was recently reported to be overexpressed in about
10.5% of human cancers (Michael and Oren 2002; Toledo and Wahl 2006). In
fact, because of the role that MDM2 plays in p53 regulation, MDM2 has become
a therapeutic target with a focus on liberation of p53 from degradation in cancers
where p53 remains wild-type. Molecules that specifically target MDM2, such as
small molecule inhibitors, like HLI98, are being tested in vitro for their therapeutic
potential. The nutlins are antagonists of MDM2, and can disrupt the MDM2-p53
binding (Vassilev 2007; Shangary and Wang 2008). Studies have shown that
expression of such molecules can restore the function of p53. In addition, the
restoration of TSGs that act upstream of p53 through interactions with MDM2
provide gene therapeutic targets. The TSG p14/ARF binds to and inhibits the
activity of MDM2, thereby stabilizing p53 activity (Sherr 2001). Gene therapy to
re-express p14/ARF is of particular importance in the context of mesothelioma,
as p14/ARF is often inactivated in this tumor type (Figure 4). The use of this
therapy, in combination with the re-expression of other TSGs that regulate
MDM2, like NF2, could achieve restoration of p53 function resulting in anticancer
activity.
Of the common chromosomal regions commonly altered in malignant
mesotheliomas (Figure 4), absent from the list is chromosome 17p, the region
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that harbors TP53 (Murthy and Testa 1999; Jaurand and Fleury-Feith 2005).
Considering that the majority of mesotheliomas retain wild-type p53, the question
becomes whether or not this wild-type p53 can still function properly. If enough
alterations in genes that help to maintain p53 activity and function take place, it is
quite possible that p53 is unable to act as a cell cycle regulator in these tumors.
The critical role of p53 is made evident not only by genetic mutations present in
over half of all human cancers, but also because of its critical role in host/tumor
response to cancer treatments like radiation and chemotherapy (Lane and
Fischer 2004). A complete understanding of the regulators of p53 function is
essential for the development of more effective treatment strategies for cancer
(Toledo and Wahl 2006).
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Hypothesis

The hypothesis of this study is that inactivation of NF2 plays a critical role in
cellular growth deregulation by altering normal regulation of MDM2 and thus p53
levels. This hypothesis was tested through the following specific aims:

Specific Aim 1: Analyze the role of the NF2 gene in regulating p53 function and
cellular growth in “normal” mesothelial cells and mesothelioma cell culture
models. Normal function of merlin was restored by transfection of a wild-type
NF2 construct in a mesothelioma cell culture model. Merlin function was reduced
in non-cancerous mesothelial cells by shRNA knockdown.

Specific Goal 2: Analyze the role of the NF2 gene in an in vivo model of pleural
mesothelioma development. A heterozygous NF2 knockout mouse model was
used to follow closely the early events in tumor development. NF2 status, time to
tumor development, phenotypic and p53-related gene expression changes were
monitored.
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CHAPTER 1

shRNA Suppression of NF2 Induces Disruption of Normal Cell Cycle
Control Mechanism by Altering p53 Function

Abstract

The tumor suppressor gene neurofibromatosis type 2 (NF2) is inactivated in the
majority of malignant mesotheliomas, an aggressive cancer strongly associated
with asbestos exposure. The consequences of this inactivation are not well
understood. Conversely, the major tumor suppressor gene TP53 is rarely found
mutated in mesothelioma tumors, but p53 activity may be regulated by other
mechanisms during progression of this disease. Using shRNA directed against
NF2, we assessed the possibility that loss of NF2 negatively affects p53 function
in a non-tumor mesothelial cell line. NF2 suppression resulted in loss of cell
cycle control correlating directly or indirectly with aberrant p53 function.
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Introduction

Considered the “Genome Gatekeeper,” p53 (the protein product of the
TP53 gene) is a transcription factor that initiates several protective pathways
following DNA damaging events (Lane 1992; Levine 1997; May and May 1999).
Depending on the type of cellular stress, p53 is activated to initiate DNA repair
mechanisms, cell cycle arrest, or apoptosis (Rotter et al. 1994; Gottlieb and Oren
1998; Oren 1999). Thus, loss of p53 function can be critical for the developing
cancer cell. While TP53 is mutated in most forms of human cancer, in those
where TP53 remains wild type, loss of other tumor suppressor genes upstream
of TP53 may contribute to a decrease in function of the gene (Ludlow 1993;
Marine and Jochemsen 2005; Zhang et al. 2008). Such is the case for malignant
pleural mesothelioma (MPM), in which the majority of MPM patients retain wildtype TP53 genetics, but it is unknown if the p53 protein retains proper function
(Murthy and Testa 1999).
MPM is a rare but aggressive cancer usually associated with exposure to
asbestos (Treasure and Sedrakyan 2004; Altomare et al. 2005; Tan and
Treasure 2005). Genomic analysis of mesothelioma has revealed a series of
related sub-chromosomal deletion regions that could be involved in loss of cell
cycle regulation. Within the regions affected, crucial regulatory genes implicated
include p16 (INK4a) and p14 (ARF) on 9p, and NF2 on 22q (Murthy and Testa
1999; Jaurand and Fleury-Feith 2005; Musti et al. 2006). It is possible that
inactivation of tumor suppressor genes thought to be involved in p53 regulation,
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such as NF2 or p14/ARF, could hinder its ability to act as the “genome keeper”
following cellular stress (Kamijo et al. 1998; Pomerantz et al. 1998; Zhang et al.
1998).
NF2 is inactivated by mutation or loss of heterozygosity in the majority of
mesotheliomas, but the significance of this loss is not well understood (Baser et
al. 2002; Carbone et al. 2002; Altomare et al. 2005; Tan and Treasure 2005;
Yang et al. 2008; Weiner and Neragi-Miandoab 2009). Loss of function of tumor
suppressor genes can be a critical step leading to abnormal growth, negatively
affecting cellular processes including apoptosis, proliferation, cell-cell
communication, cell motility, differentiation, as well as others (Sainio et al. 1997;
Gutmann et al. 1999; Morrison et al. 2001; Shaw et al. 2001; Sherman and
Gutmann 2001; Lallemand et al. 2003; McClatchey and Giovannini 2005; Xiao et
al. 2005; Curto and McClatchey 2008). Merlin, the protein product of the NF2
gene, is activated by regulatory cues to play a role in these processes,
depending on cell type.
Merlin is activated in vitro during cellular stress events such as serum
deprivation or increased cell:cell contact ratios, but the exact molecular
consequences of this activation remain to be elucidated (Shaw et al. 1998b;
Morrison et al. 2001; McClatchey 2003; Xiao et al. 2005). Following activation,
merlin localizes to the cell membrane (Sherman et al. 1997; Shaw et al. 1998a;
McClatchey and Giovannini 2005; Curto and McClatchey 2008). This
translocation is considered to be rare among tumor suppressor genes, as most
function intracellularly to regulate cell cycle events (McClatchey and Giovannini
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2005; Curto et al. 2007). The associations that merlin forms with membrane
proteins suggest that merlin may be involved in signaling cascades upstream of
p53 that may be required to initiate growth arrest.
In this study, we show that suppression of NF2 gene expression using
small hairpin RNA (shRNA) in a nonmalignant mesothelial cell line results in an
inability of p53 to appropriately respond to stress. Thus, p53 was unable to
initiate exit of the cell cycle either by undergoing apoptosis or by activating
appropriate cell cycle checkpoints. A better understanding of cell cycle
regulatory changes resulting from the suppression of NF2 in mesothelial cells
may provide valuable insight into the molecular mechanisms taking place in
mesotheliomas as well as other tumor types with NF2 inactivation.
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Results

Using an in vitro model for pleural mesothelial cell growth, MeT5a cells
were transduced with 5 different shRNA constructs, each targeted against a
different region of the NF2 mRNA transcript (Figure 8a). The shRNA target
sequences are listed in Table 2. In addition, MeT5a cells were also stably
transduced with a BLAST-negative control version of the Mission shRNA
construct. The BLAST-negative vector contains a shRNA insert that has at least
a 4-bp mismatch with any known mouse or human gene. Following generation of
stably transduced clones, three different MeT5a/NF2-shRNA clones (9973-6,
9974-5, and 9977-2) were chosen for further analysis (Figure 8b). Protein was
harvested from cells plated at both low cellular density (LCD) and high cellular
density (HCD). This was done to assess the additional role of merlin activation
status, merlin being activated in vitro during conditions like HCD (Morrison et al.
2001; Sherman and Gutmann 2001; Lallemand et al. 2003; McClatchey and
Giovannini 2005; Xiao et al. 2005). Of the selected clones, significant decreases
in merlin suppression compared to the control clone (MeT5a/CNT9) were found
at both LCD and HCD depending on the clone.
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FIGURE 8
a) NF2 mRNA targets of the five Mission shRNA vectors used.

1 base pair (b.p.)

NF2 Transcript Variant 1

39977 shRNA
39976 shRNA
1,944 to 1,964 b.p.
1,191 to 1,211 b.p.
39975 shRNA
39974 shRNA
1,290 to 1,310 b.p.
2,092 to 2,112 b.p.

b) Merlin suppression at LCD and HCD.
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6,021 b.p.

39973 shRNA
4,648 to 4,668 b.p.

Figure 8. MeT5a cells treated with NF2 shRNA.

Five shRNA designs were targeted against different regions of the NF2 mRNA
transcript (8a). Following selection of stably-transfected MeT5a cells, clones
were selected and then analyzed for amount of merlin suppression as compared
to MeT5a/CNT9 cells using Western blot analysis. The amount of merlin
suppression was quantified using densitometry normalized to α-Tubulin (8b).
Mean fold changes of merlin expression for each clone vs. MeT5a/CNT9 were:
9973-6 LCD=0.657±0.305, HCD=0.507±0.035*; 9974-5 LCD=0.234±0.129*,
HCD=0.353±0.161; 9977-2 LCD=0.246±0.103*, HCD=0.463±0.195.
Protein expression changes are representative of three individual experiments.
*p<0.05 using unpaired t-test.

55

Table 2. shRNA Sequences Directed Against NF2 mRNA.
shRNA
Name
9973*
9974*
9975
9976
9977*

Clone ID
NM_000268.24648s1c1
NM_000268.22092s1c1
NM_000268.21290s1c1
NM_000268.21191s1c1
NM_000268.21944s1c1

Target
Region
3UTR
CDS
CDS
CDS
CDS

shRNA Target Set Sequence
CCGGCGGGCTTTGTTTCCTTCTTTACTCGAGTAAAGAAGGAA
ACAAAGCCCGTTTTTG
CCGGGCTCTGGATATTCTGCACAATCTCGAGATTGTGCAGAA
TATCCAGAGCTTTTTG
CCGGGCTTCGTGTTAATAAGCTGATCTCGAGATCAGCTTATT
AACACGAAGCTTTTTG
CCGGCCCGTGGAATGAAATCCGAAACTCGAGTTTCGGATTT
CATTCCACGGGTTTTTG
CCGGCGACTTCAAAGATACTGACATCTCGAGATGTCAGTATC
TTTGAAGTCGTTTTTG

* Clones generated from these sequence targets were used for further analysis.
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Under in vitro conditions of HCD, normal cells will typically enter a
quiescent state due to either depletion of nutrients provided in the media or
limited space to proliferate. Merlin has previously been show to play a role in
contact inhibition of growth, possibly through CD44 binding (Shaw et al. 1998b;
Morrison et al. 2001). Suppression of merlin in MeT5a cells allowed for continued
increase in cell density at confluence during growth curve analysis (Figure 9).
While the growth rate of NF2-shRNA MeT5a clones slowed, the cell number at
days 10, 14, and 18 were significantly higher than those for MeT5a/CNT9 cells.
In comparison, MeT5a/CNT9 cells reached maximum growth after 10 days, and
then appeared to reach a plateau phase of growth. These results indicate a role
for merlin in maintaining normal growth in a mesothelial cell model.
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FIGURE 9
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Figure 9. Growth curve analysis of MeT5a/CNT9 and NF2-shRNA
transduced MeT5a cells.

As an initial analysis of cellular phenotype following shRNA suppression, growth
curves were used to determine changes related to both contact inhibition of
growth as well as possible proliferation rate changes. Clones generated from
MeT5a transductions were plated in triplicate in 6 well plates to be counted on
days 1, 4, 7, 10, 14, and 18, and average numbers from triplicate wells were
used for statistical analysis. Although there was not an apparent increase in
proliferation during growth phase of the growth curve, there were significant
differences in saturation densities between NF2-shRNA transduced clones as
compared to MeT5a/CNT9 cells.
n=3
*p<0.05, **p<0.01, and ***p<0.001 using a Two-way ANOVA.
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The effect that merlin activation has on downstream signaling pathways in
mesothelial cells is not well understood. The loss of contact inhibition of growth
as seen in the growth curves suggest that normal cell cycle control mechanisms,
such as proliferation and/or cell cycle exit through either apoptosis or cell cycle
arrest, have been disrupted. Bromodeoxyuridine (BrDU) was used to analyze
alterations in cell cycle progression, as BrDU is incorporated into proliferating
cells during S phase of the cell cycle when DNA replication takes place. To
determine if merlin suppression changed the ability of cells to proliferate during
conditions of high cellular density (HCD), which occurs at the plateau phase of
the growth curve (Figure 9), cells were incubated with BrDU for 24 hours. All
merlin-suppressed clones showed an increase in BrDU incorporation, indicating
that merlin suppression results in either an increased rate of proliferation or an
increase in the amount of cells capable of transitioning from G1 to S phase
(Figure 10a and 10b). To exclude the possibility that cell number at the time of
seeding might influence these results, two different seeding densities were used.
Differences in seeding number did not change the increased ability of the NF2suppressed clones to continue proliferating after reaching confluency.
To further assess possible proliferative advantages of merlin suppression
under conditions of cellular stress, BrDU uptake was measured following
exposure to 5 J/m2 of ultraviolet radiation (UV). There was only a slight increase
in BrDU uptake in NF2-shRNA clones as compared to MeT5a/CNT9 cells plated
at 10,000 cells/well. NF2-shRNA clones cells plated at 20,000 cells/well were
still capable of DNA replication following exposure to UV as observed through an
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increase in uptake of BrDU as compared to MeT5a/CNT9 cells, although these
values were not significant. The ability to proliferate even under conditions of
cellular stress is evidence that merlin suppression has pushed these mesothelial
cells towards a more transformed phenotype, possibly related to alterations in the
p53 cell cycle checkpoint.
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FIGURE 10
a) Basal BrDU uptake in MeT5a clones.

b) BrDU uptake in MeT5a clones following UV exposure.
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Figure 10. Alterations in BrDU incorporation in MeT5a cells.

Cells were plated at 10,000 cells/well, which is confluent in a 96 well plate. NF2shRNA clones showed a significant increase in BrDU uptake as compared to
MeT5a/CNT9 cells. Even at an increased cellular density, NF2-shRNA still were
able to proliferate at an increased rate as compared to MeT5a/CNT9 cells, with
significant values achieved in clones 9974-5 and 9977-2 (10a). After exposure to
5Joules/cm2 UV, although there was little change in the amount of BrDU
incorportation in cells plated at 10,000 cells/well, there was an increase in the
amount of BrDU uptake in NF2-shRNA cells compared to MeT5a/CNT9 although
these values were not significant (10b).
n=3. *p<0.05 and **p<0.01 using a Two-way ANOVA.
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MDM2 plays a major role in p53 degradation, and there is evidence that
has linked merlin to MDM2 degradation in mouse fibroblast 3T3 cells (Kim et al.
2004). We analyzed the result of merlin suppression on changes in the levels of
MDM2 expression using western blot analysis, and found that in NF2-suppressed
clones there was an increase in MDM2 expression as compared to MeT5a/CNT9
cells, especially at LCD (Figure 11). This increase in MDM2 may result in
increased p53 degradation and thus a decrease in p53 activity, which may
explain the continual BrDU uptake at both HCD and after UV exposure.
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FIGURE 11
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Figure 11. Protein expression changes in MDM2 expression.

Alterations if the protein expression levels of MDM2 in all MeT5a clones were
analyzed via Western blot analysis. NF2-suppressed clones had increased
expression of MDM2 as compared to MeT5a/CNT9 cells, which was more
pronounced during LCD conditions. Protein expression changes were quantified
using densitometry normalized to α-Tubulin. Mean fold changes of MDM2
expression for each clone vs. MeT5a/CNT9 were: 9973-6 LCD=2.902±1.245,
HCD=2.222±.662; 9974-5 LCD=4.646±2.682, HCD=1.613±0.347; 9977-2
LCD=4.238±2.982, HCD=1.127±0.0.090. Protein expression changes are
representative of three individual experiments. While there were no significant
changes found using One-way ANOVA, these data do suggest a trend towards
increased MDM2 expression in merlin suppressed clones.
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We further analyzed protein expression changes in key cell cycle genes
that act at the G1-S phase transition point that may be affected by merlin
suppression. Merlin has been shown to inhibit Cyclin D1, which has a critical role
in allowing cells to driving cells into S phase of the cell cycle (Xiao et al. 2005).
Cyclin D1 is a critical integrators of mitogenic signals for cell cycle progression,
thus inhibition of the protein could result in fewer cycling cells (Diehl 2002;
Vermeulen et al. 2003). At both LCD and HCD, there was an increase in Cyclin
D1 protein expression in all NF2-shRNA clones as compared to MeT5a/CNT9
cells however these increases were not significant (Figure 12a).
In addition, we assessed expression changes in the cell cycle checkpoint
gene, p21(CDNKa). DNA stress is detected as cells are preparing to move from
the phase G1 of the cell cycle into S phase, p53 acts as a direct transcription
factor for the p21 gene to initiate cell cycle arrest (el-Deiry et al. 1993; Harper et
al. 1993; el-Deiry et al. 1994). As cell:cell contact increases in a HCD in vitro
environment, this results in cellular stress that may activate p53 and
subsequently p21. At both LCD and HCD, p21 was decreased in clones 9974-5
and 9977-2 as compared to MeT5a/CNT9, while there was little change in clone
9973-6 (Figure 12b). Although there was no significant differences found, these
results begin to indicate that merlin may be upstream of p53.
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FIGURE 12
a) Immunoblot of Cyclin D1 expression.
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b) Immunoblot of p21 expression.
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Figure 12. Protein expression in genes involved in cell cycle progression.

Western blot analysis was used to assess protein expression changes in genes
involved in cell cycle progression. In all NF2-shRNA suppressed clones there
was an increase in Cyclin D1 expression as compared to MeT5a/CNT9 cells,
although these increases were not significant. At HCD, the amount of Cyclin D1
expression decreased slightly as compared to values seen at LCD (12a). Protein
expression changes were quantified using densitometry normalized to α-Tubulin.
Mean fold changes for Cyclin D1 expression for each clone vs. MeT5a/CNT9:
9973-6 LCD=1.648±1.131, HCD=0.895±0.130; 9974-5 LCD=1.522±0.298,
HCD=1.240±0.225; 9977-2 LCD=1.533±0.255, HCD=1.553±0.0.538.
There was a decrease in p21 expression as compared to MeT5a/CNT9 cells at
both LCD and HCD although not significant (12b). Protein expression changes
were quantified using densitometry normalized to α-Tubulin. Mean fold changes
for p21 expression for each clone vs. MeT5a/CNT9: 9973-6 LCD=0.551±0.325,
HCD=0.433±0.189; 9974-5 LCD=1.012±0.375, HCD=0.8564±0.369; 9977-2
LCD=0.561±0.214, HCD=0.601±0.0.388.
Protein expression changes are representative of three individual experiments.

70

We also determined if cell cycle exit through apoptosis had been affected
in response to decreased merlin. Exposure to UV radiation is a proven method
for inducing apoptosis through p53-dependent pathways, primarily by acting as a
direct transcription factor for the pro-apoptotic Bcl2 family member, Bax
(Maltzman and Czyzyk 1984). As a measure of apoptosis, DNA fragmentation
was quantified 24 hours post-UV exposure. NF2-shRNA suppressed clones had
a significant decrease in the amount of apoptotic induction following UV exposure
as compared to the apoptotic response seen in MeT5a-CNT9 cells (Figure 13a).
Additionally, Bax protein expression changes were quantified 3 hours post-UV
exposure (Figure 13b). Fold induction of Bax protein in NF2-shRNA suppressed
clones was decreased in both basally and in UV-exposed samples compared to
MeT5a/CNT9 Bax protein expression. This suggests that p53 is functioning in
MeT5a/CNT9 cells as its downstream target, Bax, is activated. Even partial
suppression of merlin altered this p53 responsive element indicating that merlin
is an essential element for effective p53 function.
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FIGURE 13
a) Apoptotic induction following UV exposure.

b) Bax protein expression changes.
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Figure 13. Changes in apoptotic response of MeT5a clones after UV
exposure.

The ability to respond to apoptosis induction was analyzed by a DNA
fragmentation assay (TiterTacs, Trevigen) 24 hours post-exposure to 5J/cm2 UV.
NF2-shRNA clones showed a significant decrease in the percent of apoptosis
following exposure as compared to MeT5a/CNT9 cells (13a). A 3 hour UV
exposure was also used to induce Bax protein expression, which can be
correlated to p53 activity. Western blot analysis indicates that MeT5a/CNT9 cells
express more Bax protein than NF2-shRNA clones (13b). Protein expression
changes were quantified using densitometry normalized to α-Tubulin. Mean fold
changes for Bax expression for each clone vs. MeT5a/CNT9: 9973-6
Basal=0.487±0.085*, UV=0.407±0.0.090*; 9974-5 Basal=0.218±0.218, UV=0.619
±0.028**; 9977-2 Basal=0.834±0.311, UV=0.681±0.0.076.
n=3 for TiterTacs. **p<0.01 using One-way ANOVA for TiterTacs.
Protein expression changes are representative of three individual experiments.
*p<0.05 using unpaired t-test for Western blot fold change analysis.
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Conclusions

Genetic mutations that result in the disruption of cell-signaling events,
such as those that interfere with cell proliferation or contact inhibition of growth,
can have extreme consequences (Hanahan and Weinberg 2000; Evan and
Vousden 2001). When considering neoplastic development, altering these tightly
regulated cellular processes results in uncontrolled cell growth as well as
potential metastasic behavior (Tachibana et al. 2005; Johansson and Persson
2008). A non-cancerous pleural mesothelial cell line was used to assess cellcycle alterations and protein expression changes that take place following merlin
suppression that could contribute to mesothelioma development. Here we have
shown that NF2 contributes to dysregulation of cellular activities in mesothelial
cells. Suppression of merlin resulted in loss of contact inhibition of growth as
well as an increased ability to progress through the cell cycle, even in the
presence of cellular stress. To this end, we found that merlin plays a crucial role
in cell cycle exit, as partial suppression of merlin resulted in blockage of both
apoptotic and cell cycle arrest mechanisms.
Interactions that can take place between the membrane and the
cytoskeleton may be an avenue that allows merlin to react to regulatory cues
signaling downstream genes for growth arrest (Tsukita et al. 1994; Sainio et al.
1997; Sherman et al. 1997; Shaw et al. 1998a; McClatchey and Giovannini 2005;
Curto and McClatchey 2008). Merlin—also known as Moesin, Ezrin, and/or
Radixin-like protein—is a member of the ERM family of proteins. Merlin and the
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ERMs share certain structural similarities, and are a part of the superfamily band
4.1 because of the conserved four-point one, ezrin, radixin, moesin (FERM)
domain (Shaw et al. 1998a; Lim et al. 2000; Morrison et al. 2001; Sun et al. 2002;
McClatchey 2003). The FERM domain may be a linker between the membrane
and the cytoskeleton, and ERMs are thought to be involved in the organization of
cortical membrane domains that interface with the extracellular environment
linking membrane-associated proteins to intracellular components (Shaw et al.
1998b; Curto and McClatchey 2008). Localization to the cytoskeletal membrane
after activation suggests that, by mere proximity, merlin is not likely to directly
interact with cell cycle regulators but instead may signal upstream of such
regulators to inhibit cell cycle progression (McClatchey and Giovannini 2005).
This upstream regulation has implications for the role of NF2 in cell cycle control,
such that merlin may be involved in both cell cycle exit and cell proliferation
through p53 regulatory mechanisms. When NF2 is mutated, merlin is incapable
of localizing to cell membrane surfaces and therefore cannot respond to such
environmental cues to signal p53 activity (Curto and McClatchey 2008).
Alterations in the cellular response to increased cell:cell contact following
suppression of merlin suggests that the inactivation of NF2 may directly or
indirectly influence the negative regulation of p53, contributing significantly to
tumor progression. NF2-shRNA cells had a significant advantage in their ability to
progress through the cell cycle as compare to MeT5a/CNT9 cells. In the
MeT5a/CNT9 cells, inadequate space for cellular division to take place, as well
as lack of nutrients due to increased rate of consumption, were sufficient to
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activate p53 and initiate cell cycle exit. Although no change was found in p53
protein expression between following merlin suppression (data not shown), the
increase in protein expression of two p53-regulated response elements (p21 and
Bax) in MeT5a/CNT9 cells is indicative of this p53 activity. Conversely, the
decrease in p53 function in the MeT5a-NF2-shRNA clones suggests that NF2
may be involved upstream in p53 signaling pathways. This decrease in p53
activity resulted in a decrease in the ability to exit the cell cycle through apoptosis
as well as exit through cell cycle arrest, contributing to the increased proliferation
seen at HCD.
The exact mechanisms by which merlin may control p53 activity has yet to
be established. Kim et al. 2004 demonstrated a tight link between the merlin and
MDM2, ultimately leading to the dysregulation of p53. In this report, it was shown
that merlin is responsible for MDM2 degradation using 3T3 fibroblast cells (Kim
et al. 2004). MDM2 is involved in an autoregulatory feedback loop with p53,
whereby p53 is a transcription factor for MDM2 after which MDM2 can then
ubiquitinate p53, tagging it for degradation (Levine 1997; Zhang et al. 1998;
Michael and Oren 2002; Brooks and Gu 2006; Zhang et al. 2008). Here we have
shown that merlin resulted in increased MDM2 expression in mesothelial cells as
well, which is an unexplored avenue for tumor progression in mesothelioma
tumors.
Also contributing to cell cycle progression in NF2-suppressed cells is
increased Cyclin D1 expression. The D-type cyclins are one of the necessary
components involved in entry into S phase of the cell cycle. One of the molecular
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targets of Cyclin D1 is RB, responsible for phosphorylation RB allowing cells to
transition into S phase (Lukas et al. 1994; Resnitzky and Reed 1995; Shackelford
et al. 1999; Bali et al. 2004; Tachibana et al. 2005). RB, like TP53, is another
tumor suppressor gene rarely found mutated in mesothelioma tumors (Rouleau
et al. 1993; Jaurand and Fleury-Feith 2005; Kumar and Kratzke 2005). Further
investigation of this pathway will provide more insight into merlin cell cycle
regulation, in particular its role in the G1 to S phase transition. If merlin is also
upstream of RB, inactivation of merlin could be a critical step allowing cells to
continue proliferation.
Here we have shown that merlin plays in cell cycle control includes
alterations regulatory cues of both cell cycle exit mechanisms, including both
apoptosis and cell cycle arrest, as well as proliferation in mesothelial cells. The
vast array of cellular processes that are disrupted by decreased merlin
expression strengthens our knowledge of the role NF2 plays as a critical
regulator of cell growth. In particular, our finding that the p53 response to UV
damage is negatively regulated by merlin suppression provides novel insight into
the molecular mechanisms involved in merlin activation. Thus, the processes
involved in the activation, translocation, and regulation of merlin can ultimately
affect p53 activity. Therefore future studies aimed at delineating merlin
interacting molecules and their functional relationships will be critical for
understanding the NF2/p53 pathway.
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Methods
Cell Culture
The MeT5a cell line was grown in Medium199 with Earle's BSS, 0.75 mM Lglutamine and 1.25 g/L sodium bicarbonate supplemented with 3.3 nM epidermal
growth factor (EGF), 400 nM hydrocortisone, 870 nM insulin, 20 mM HEPES,
10% fetal calf serum, penicillin streptomycin, sodium pyruvate, and non-essential
amino acids. Following transduction with lentiviral vectors, the addition of
puromycin (1.8 µg/ml) to the media was used for selection of stably-transduced
clones.
Lentiviral shRNA Virus Production and Cell Transductions
MeT5a cells were transduced with 5 different Mission shRNA constructs (SigmaAldrich, St Louis, MO), each targeted against a different region of NF2 mRNA.
MeT5a cells were also transduced with the PLKO.1 Mission shRNA control
plasmid (Sigma-Aldrich, St Louis, MO), which consists of a scrambled insert
sequence that is BLAST negative. Generated clones were screened to
determine the amount of merlin suppression at 70% confluence. NF2
suppressed clones chosen to use for further analysis had a decrease in merlin
expression ranging from 45-80% as compared to a control plasmid transduced
MeT5a cells.
Growth Curves
Cells were plated into 6 well plates at 10,000 cells per well. Cells were covered
with 3 mL of media and incubated at 37°C. Media was changed every 3 days.
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At each time point, cells were counted in triplicate (3 wells of cells per count)
using a hemacytometer.
ImmunoBlots
Cells were plated at 90,000 cells/well into 6 well plates for LCD and 300,000
cells/well for HCD and incubated 24 hours. At time of protein harvest, LCD
samples were ~60% confluent for LCD and HCD samples were >90%. At the
time of protein harvest, media was removed and cells were washed with
Phosphate Buffered Saline (PBS). Protein was harvested in PBS-TDS lysis
buffer (0.1% Triton X-100; 12.6 mM Sodium deoxycholate; 3.7 mM SDS; 1 mM
EDTA; and 0.2 mM PMSF containing phosphatase and protease inhibitors
(Sigma Alrdich, St Louis, MO)). Protein levels were measured using the BioRad
Protein DC assay (Bio-Rad, Hercules, CA). Samples were loaded onto a 4-12%
Bis-Tris Nupage gel (Invitrogen, Carlsbad, CA) then transferred onto a PVDF
membrane (Millipore, Bedford, MA). Membranes were blocked and the primary
antibody added. Following incubation with the primary antibody, membranes
were washed with PBS and Tween-20 (0.1% Tween-20) (PBS-T(0.1%), and a
goat anti-mouse or goat anti-rabbit secondary antibody was added. Membranes
were washed with PBS-T (0.1%) prior to chemiluminescence detection using the
Immobilon Detection kit (Millipore, Bedford, MA). Blots were stripped and
reprobed for α-Tubulin as a loading control. Antibodies used include: NF2
(A19), MDM2 (2A10), and p21 (C-19) from Santa Cruz Biotechnology, Santa
Cruz, CA; Cyclin D1 (DCS-6) and Bax (AM32) from Calbiochem, San Diego, CA;
and α-Tubulin from Sigma-Aldrich, St Louis, MO.
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BrdU Incorporation Assay
Cells were plated in triplicate in two 96 well plates (one for exposure, one for no
exposure control) at cellular densities of 10,000 cells/well and 20,000 cells/well.
24 hours after plating, media was removed and replaced with 50 µl PBS and
exposed to UV. Immediately following exposure, PBS was removed and
replaced with fresh media with BrDU was added. Cells were placed in incubator
for 24 hours, the amount of BrDU labeled DNA was quantified following the
manufacturer’s protocol (Calbiochem, San Diego, CA).
UV Exposure
For experiments utilizing UV exposure to induce DNA damage for protein
expression changes, cells were plated in 6 well culture dishes at 90,000
cells/well. The next day, media was removed and wells were covered with 500 µl
PBS. Cells were placed in a Stratagene Stratalinker 1800 with no plate covers
and then exposed to 5J/m2. Following exposure, PBS was removed and
replaced with media. Cells were incubated at 37°C for 3 hours, media was
removed, cells were washed with PBS, and protein was harvested in protein lysis
buffer as previously described.
For apoptosis and BrDU UV exposures, media was removed from incubated cells
and replace with 100ul of PBS. After cells were placed in the Stratagene
Stratalinker 1800, covers of plates were removed and plates were then exposed
to 5J/m2. PBS was removed and replaced with fresh, and the cells were
incubated at 37°C for 24 hours.
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TiterTacs Apoptosis Assay
Cells were plated in triplicate in two 96 well plates (one plate for UV exposure,
one plate served as no exposure control) at 40,000 cells/well. 48 hours after
plating, cells were exposed to either UV or Camptothecin. TiterTacs (Trevigen,
Helgerman, CT) was used according to manufacturers protocol to assess DNA
fragmentation.
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CHAPTER 2

Differential Protein Expression in Human Mesothelioma Cell Lines and
Alterations in Cell Growth Following Reintroduction of NF2 Protein

Abstract

Malignant pleural mesothelioma (MPM) is an extremely aggressive form of
cancer with a strong link to asbestos exposure. Patients diagnosed with MPM
have a very poor prognosis with a median survival time of approximately 2 years.
One of the most commonly inactivated tumor suppressor genes during the
course of mesothelioma development is Neurofibromatosis Type 2 (NF2).
Additionally, TP53 mutations are rare in MPM, suggesting that aberrant p53
function may be due to upstream alterations in its regulation. In this study, we
assessed differences in the expression of proteins with a known link to TP53
activity in human mesothelioma cell lines and a nonmalignant mesothelial cell
line. Cell cycle alterations were analyzed in response to full-length NF2 gene
construct introduction using a human MPM cell line that does not express Merlin,
the protein product of NF2.
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Introduction

The TP53 tumor suppressor gene is arguably the most important tumor
suppressor gene involved in the development of human cancer (Lane 1992;
Levine 1997; Oren 1999). While TP53 is mutated in a majority of human
cancers, a significant number of patients with no detectable mutations still go on
to develop cancer (Danovi et al. 2004). This suggests that genetic or functional
aberrations in genes that regulate p53, the protein product of TP53, are a factor
in human cancers that retain wild-type TP53, including MPM.
MPM is an aggressive cancer with a complex etiology. Mesothelioma
tumors form in the mesothelial layer lining certain body cavities, the most
common of these occurrences is in the pleural mesothelial layers that encase the
lung. Patients diagnosed with these relatively rare cancers have a poor
prognosis, with patients often succumbing to the disease within 2 years postdiagnosis (Guinee and Allen 2008). It is hypothesized that in MPM, an
accumulation of mutations in tumor suppressor genes, such as p16/INK4a
(CDKN2A) and p14/ARF (CDKN2B) on 9p, and Neurofibromatosis type 2 (NF2)
on 22q, occur during the latency period of 20-40 years following exposure to
asbestos(Altomare et al. 2005; Kumar et al. 2005). Mutations in the NF2 gene
occur at a particularly high frequency in MPM, whereas mutations in TP53 are
rare (Sekido et al. 1995; Murthy and Testa 1999). Kim and colleagues (2004)
demonstrated in 3T3 mouse fibroblast cells that inactivation of NF2 can indirectly
affect p53 function through degradation of MDM2, a negative regulator of p53.
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This regulatory pathway of p53 has not yet been examined in human mesothelial
cells.
In order to develop a more effective treatment strategy for patients with
MPM, as well as other cancers involving wild-type TP53, we must gain a more
thorough understanding of the molecular changes that occur during disease
development. Analysis of four pleural mesothelial cell lines, nonmalignant and
malignant, revealed a dramatic difference in expression of the p53 protein as well
as a possible link between merlin, the protein product of NF2, and MDM2 protein
expression. We further analyzed cell cycle changes after reintroduction of a fulllength version of NF2 in a merlin-negative mesothelioma cell line.

88

Results
The TP53 tumor suppressor gene is of central importance in the regulation
of cell proliferation and/or cell death following DNA damage. The activity of p53
is tightly regulated in response to cell signaling molecules, including the negative
regulator MDM2, and its structural analog, MDM4 (Marine and Jochemsen 2005;
Brooks and Gu 2006). Using the pleural nonmalignant mesothelial cell line,
MeT5a, and the pleural mesothelioma cell lines, H-meso-1, H2052, and H28, we
analyzed protein expression changes using Western blots. We did not observe a
significant change in the expression of MDM4 among the cell lines in this study
(Figure 14a and 14b), however there is an increased MDM2 expression in the Hmeso-1 cell line when compared to MeT5a (Figure 14a and 14c). In addition,
there is a significant decrease in the expression of p53 in the tumor cell lines
when compared to the nonmalignant mesothelial cell line (Figure 14a and 14d).
Interestingly, p53 expression in the H-meso1 cell line is nearly undetectable and
significantly lower than both the H28 and H2052 lines, respectively. Of particular
interest, merlin is undetectable in the H-meso1 cells (Figure 14a and 14e).
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Figure 14
a) Immunoblots for merlin and MDM2 expression.

b) Densitometry analysis of immunoblots for MDM4 expression.

c) Densitometry analysis of immunoblots for MDM2 expression.
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d) Densitometry analysis for p53 expression.

e) Densitometry analysis for merlin expression.
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Figure 14. Immunoblots of protein expression between the MeT5a and
mesothelioma cell lines.

Protein expression changes were analyzed via Western blot. The H-meso1 cell
line had no detectable NF2 expression (14a and 14b). While there was
increased expression of merlin in the H2052 and H28 cell lines as compared to
MeT5a, the differences were not significant (14b). A trend towards increasing
expression of MDM2 was seen in the H-meso-1 cell line, although the differences
were not significant (14a and 14c). The MeT5a line had significantly higher
expression of p53 than all three mesothelioma cell lines (Figure 14d and 14e).
Both the H2052 and the H28 lines had significantly higher expression of p53 than
the H-meso-1 cells (14d and 14e).
*p<0.05 and indicates a significant difference when compared to MeT5a.
^p<0.05 and indicates a significant difference when compared to H2052 and
H28. Protein expression changes were quantified using densitometry normalized
to β-Actin or α-Tubulin. All statistics were conducted using densitometry from
three blots from independent experiments using unpaired t-test.
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To investigate cellular growth conditions and specific downstream
molecular targets that may result from aberrant merlin expression, we reintroduced NF2 in the H-meso-1 cell line. In order to achieve consistent levels of
merlin expression and to achieve expression for growth curve analysis (21 days),
it was important to utilize a stable transfection technique. An H-meso1 cell line
already containing a Tet-repressor vector was transfected with either a pTREX
control vector or a pTREX vector with a full-length open reading frame version of
NF2 (IOH23119, NF2 Complete CDS, Invitrogen, Carlsbad, CA). Clones positive
for merlin or the control vector were selected using G418. The H-meso-1 clones
for the control vector (H-meso-1/CNT) or NF2 (H-meso-1/NF2), were analyzed
for merlin expression using Western blot analysis (Figure 15a).
To determine the effect that merlin re-expression had on MDM2, we also
analyzed changes in MDM2 protein levels in the transfected H-meso-1 clones. It
has been shown that merlin is activated in vitro during conditions like high cellular
density (HCD).(Morrison et al. 2001; Sherman and Gutmann 2001; Lallemand et
al. 2003; McClatchey and Giovannini 2005; Xiao et al. 2005) Thus, protein was
harvested from cells plated at both low cellular density (LCD) and high cellular
density (HCD) to assess protein expression changes dependent upon merlin
activity. H-meso-1/NF2 cells showed a slight decrease in MDM2 protein levels at
HCD when compared to the H-meso-1/CNT cells, although these values were
not significant (Figure 15b). Next, we were interested in whether or not these
alterations in merlin and MDM2 protein would have an effect on p53 status and
cellular phenotype.

93

FIGURE 15
a) Merlin expression in H-meso-1 cells.

b) MDM2 expression in H-meso-1 cells.
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Figure 15. Western blot of NF2 and MDM2 expression changes in H-meso-1
cells.

Protein was harvested from H-meso-1/NF2 and H-meso-1/CNT cells plated at
LCD and HCD to follow protein level changes related to merlin activity status.
Harvested lysates were analyzed via Western blot analysis for merlin expression
verification (15a) and MDM2 expression changes (15b). At HCD, when merlin is
activated, there a slight decrease in MDM2 protein levels which could be related
to the increase merlin expression and/or activity.
All statistics were conducted using densitometry from three blots from
independent experiments using unpaired t-test.
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We used growth curves to determine whether there were alterations in the
cell cycle following reintroduction of NF2 in the H-meso-1 cell line. Growth
curves are a useful tool for assessing changes in both growth rate and saturation
density in vitro, the latter being a good indicator of the degree to which a cell has
been transformed. At the plateau phase of cell growth, there was a decrease in
saturation density in H-Meso-1/NF2 clones as compared to H-meso-1/CNT cells
(Figure 16). In addition, we found that the H-meso-1/NF2 cells show a shift in the
log phase portion of the growth curve, suggesting that either H-meso-1/NF2 cells
were undergoing cell cycle arrest or that growth rate itself had slowed.
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FIGURE 16
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Figure 16. Growth curves of H-meso-1/CNT and H-meso-1/NF2 cells.
Cells for each clone type were plated in triplicate into 12 well plates for each time
point to be analyzed. Every three days, cells were counted and average values
were used for statistical analysis. Merlin re-expression in H-meso-1 cells results
in a decreased rate of growth as indicated by a shift in the log phase of the curve
of H-meso-1/NF2-2 cells compared to the H-meso-1/CNT-4 log phase curve. In
addition, there is a slight decrease in saturation density of H-meso-1/NF2-2 cells
compared to the saturation density of the H-meso-1/CNT-4 cells.
Data were analyzed using a
n=3 for days 1-21, n=4 for days 1-18.
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In order to confirm that growth rate had been altered following merlin
expression, cells were labeled with BrDU. During DNA replication, BrDU is
incorporated into newly synthesized DNA strands and can be correlated with the
level of cellular proliferation. BrDU was added to the media and allowed to
incubate for 3 hours, 12 hours, or 24 hours. The amount of BrDU incorporation
was measured using an antibody directed against BrDU. At each time point, Hmeso-1/CNT cells had incorporated significantly more BrDU as compared to Hmeso-1/NF2 cells (Figure 17a, 17b, and 17c). This is supportive of the growth
curve data that show H-meso-1/NF2 cells proliferate at a decreased rate
compared to H-meso-1/CNT cells.
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FIGURE 17
a) 3 Hour BrDU Label

b) 12 Hour BrDU Label

c) 24 Hour BrDU Label
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Figure 17. BrDU incorporation in H-meso-1 clones with or without merlin
expression.

As a measure of DNA synthesis, incorporated BrDU was measured
immunochemically. The amount of BrDU incorporation was significantly lower in
H-meso-1/TR/NF2-2 clones as compared to H-meso-1/TR/CNT-4 cells at each
time point analyzed. This suggests that there was a decrease in the number of
cycling cells following NF2 re-expression in the mesothelioma tumor cell line.
* p<0.05 using t-test for each time point.
n=4 for 12 hour time point; n=5 for 3 hour and 24 hour time points.
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To further dissect the nature of the cell cycle alteration following merlin
reintroduction, measurement of DNA content was performed using flow
cytometry. This analysis provides the percentage of cells in G1, S, or G2M phase
at different levels of culture confluence. Cells were plated and allowed to
incubate for 3 or 6 days. After 3 days, both clone types were at less than 50%
confluent and determined to be LCD and the H-meso-1/NF2 cells had
significantly more cells in phase G1 compared to H-meso-1/CNT cells (Figure
18a). Although there were fewer cells cycling through S phase in H-meso-1/NF2
cells compared to H-Meso-1/CNT, this difference was not significant (Figure
18b).
After 6 days of growth, both control and NF2 clones were more than 90%
confluent and considered to be HCD. At HCD, H-meso-1/NF2 clones had an
increase in cells cycling through G1 phase of the cell cycle, as well as a decrease
in the number of cells cycling through S phase of the cell cycle compared to Hmeso-1/CNT cells. Both of these changes in cell cycle were highly significant
(Figures 18d and 18e, respectively). There was no change in the number of cells
in G2M of the cell cycle at either LCD or HCD (Figure 18c and 18f, respectively).
These DNA content results suggested that H-meso-1/NF2 cells are less able to
exit G1.
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FIGURE 18

a) LCD G1 Phase

b) LCD S Phase

c) LCD G2 Phase

d) HCD G1 Phase
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Figure 18. DNA content analysis of H-meso-1 cells to determine cell cycle
phase alterations following merlin re-expression.

DNA content analysis was analyzed on a FACScalibur flow cytometer following
propidium iodide staining. After 3 days of incubation, both control or merlinexpressing H-meso-1 cells were less than 50% confluent and termed LCD.
There was a significant increase in G1 cycling cells in H-meso-1/NF2-2 cells
compared to H-meso-1/CNT-4 cells (18a). While there was a decrease in Hmeso-1/NF2 cells cycling through S phase compared to H-meso-1/CNT-4 cells,
this difference was not significant (18b). After 6 days of incubation, both clone
types were more than 90% confluent and termed HCD. There were highly
significant differences in phases G1 and S of the cell cycle between the two clone
types (18d and 18e). No statistical differences were found in G2 phase between
the H-meso-1 clones.
* p<0.05, *** p<.001 using unpaired t-test.
n=3

104

The significant increase in cells in G1 phase of the cell cycle in H-meso1/NF2 cells suggests cell cycle arrest mechanisms may be involved. It is
generally thought that p53 initiates cell cycle arrest following DNA damage
through the upregulation of p21, for which p53 is a transcription factor. The p21
protein is known to initiate cell cycle arrest (Toledo and Wahl 2006). To
investigate if this pathway is involved, protein was harvested from both H-meso1/NF2 and H-meso-1/CNT cells at LCD and HCD conditions and p21 protein
expression was analyzed via Western blot. In the control cell line, there was
minimal p21 protein expression and there was no change in expression as cell
density increased (Figure 19a). However, in H-meso-1/NF2 cells there was an
increase in p21 protein expression under both LCD and HCD conditions as
compared to H-meso-1/CNT cells.
Further investigation of p53 activity involved activation of p53 by inducing
apoptosis using UV exposure. In response to DNA damage, p53 is a direct
transcription factor for the pro-apoptotic member of the Bcl-2 family member, Bax
(Miyashita and Reed 1995; Gottlieb and Oren 1998; Kelekar and Thompson
1998). Thus, to induce apoptosis through this p53-related pathway cells were
exposed to 5J/m2. There was no change in the amount of apoptotic induction
measured by the amount of DNA fragmentation 24 hours post-exposure (Figure
19b). An additional exposure method was used to test the possibility that Hmeso-1 cells were resistant to UV-induced apoptosis. Cells were exposed to the
topoisomerase I inhibitor, camptothecin, and DNA fragmentation assessment
showed no change in the induction of apoptosis after a 3 hour time point (Figure
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19c). Lactate dehydrogenase (LDH) activity was measured following both
exposure methods at varying time points to verify that the correct time point was
chosen for measuring apoptosis. Apoptotic induction measured after a 24 hour
exposure to UV caused the highest amount of cell death (Figure 19d).
Although there was little change in apoptotic induction between H-meso1/NF2 and H-meso-1/CNT as assessed by DNA fragmentation assays (Figure
19b and 19c), there was an increase in Bax protein in H-meso-1/NF2 cells before
and after UV exposure as compared to H-meso-1/CNT (Figure 19e). Although
differences found were not significantly different, the increase in Bax protein
expression suggests that p53 function is altered by the ability of the cells to
express merlin.
Besides alterations in p53-responsive pathways, NF2 has been shown to
inhibit Cyclin D1 (Xiao et al. 2005). Cyclin D1 is associated with the transition
from a quiescent state of the cell cycle into S phase (Lukas et al. 1994; Ladha et
al. 1998; Diehl 2002; Knudsen et al. 2006). We also found a significant decrease
in Cyclin D1 expression following reintroduction of NF2 into the H-meso-1 cell
line (Figure 19f), suggesting that not only are cell cycle checkpoints affected by
merlin but also proliferation mechanisms are responsive to merlin expression
changes.
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FIGURE 19.
a) p21 Protein Expression Changes

b) DNA Fragmentation in Response to Camptothecin Exposure

c) DNA Fragmentation in Response to UV

107

d) LDH Activity Following UV or Camptothecin Exposure

e) Bax Protein Expression Changes and Densitometry
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f) Cyclin D1 Protein Expression Changes and Densitometry
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Figure 19. Protein expression in changes in genes involved in cell cycle
control.
To investigate p53 activity, protein expression of p53-repsonsive genes was
analyzed using Western blot analysis. At HCD, when cells should exit the cell
cycle due to inadequate growth conditions, there was an increase in p21 protein
expression in H-meso-1/NF2 cells as compared to H-meso-1/CNT cells (19a).
Apoptotic response was measured using DNA fragmentation in response to both
3 hour camptothecin exposure and 24 hours post-UV exposure. Neither
treatment-type resulted in apoptosis at the measured time points (Figure 19b and
19c, respectively). LDH activity in H-meso-1/NF2 cells determined that the
highest amount of cell death could be measured at 24 hours post-UV exposure.
As a measure of p53 response to DNA damage, Bax protein expression was
quantified and showed an increased expression in H-meso-1/NF2 cells as
compared to H-meso-1/CNT cells both basally and after UV exposure, although
this difference was not significant (19e). The G1-S phase regulator, Cyclin D1,
showed a decrease in expression following reintroduction of merlin into H-meso1 cells (19f).
* p<0.05 using unpaired t-test. n=4 for camptothecin-exposed apoptosis assay;
n=3 for UV-exposed apoptosis assay.
Protein expression changes were quantified using densitometry normalized to αTubulin or GAPDH. All statistics were conducted using densitometry from three
blots from independent experiments using unpaired t-test. No significant
differences were found.
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Conclusions

As TP53 is inactivated by mutation in about half of human cancers
analyzed to date, and many times these inactivating mutations are thought to be
initiating events in tumor formation, p53 deregulation is thought to be critical for
tumor development. MPM patients are generally found to have wild-type TP53
status, despite the severity of the disease (Murthy and Testa 1999). Regulation
of p53 function can include interactions with viral proteins, such as SV40 large T
interactions, alterations in the levels of cellular proteins that can regulate p53
subcellular localization, for example Jab1, and inactivation of genes which may
help to maintain p53 function, including p14/ARF and NF2 Here we have shown
that in mesothelial cells, merlin acts upstream of p53, possibly through MDM2, to
help maintain function of the gene (Oliner et al. 1992; Moll et al. 1996; Chin et al.
1998; Pomerantz et al. 1998; Zhang et al. 2008).
Activation of p53 is a dynamic process involving induction of signaling
molecules needed to induce cell cycle arrest, DNA repair, differentiation, or
apoptosis dependent upon the type of DNA damage (May and May 1999). After
p53 has carried out its protective role, p53 acts as a transcription factor for its
own regulator, MDM2 (Oren 1999). MDM2 works to maintain p53 protein levels
and activity through ubiquitination and subsequent degradation (Michael and
Oren 2002). In the mesothelial cell lines analyzed, a trend towards increasing
MDM2 expression during conditions of reduced merlin expression was apparent.
This suggested that a disruption of other regulatory pathways had occurred.
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Inactivation of the NF2 tumor suppressor gene by mutation is most often
associated with the cancer syndrome neurofibromatosis type 2. This familial
cancer syndrome includes the development of bilateral schwannomas of the
eighth cranial nerve, meningiomas, and ependymomas (Martuza and Eldridge
1988; McClatchey 2003). In contrast to these tumors, which are primarily benign
cancers, mutations in NF2 are also frequent in the asbestos-induced cancer,
MPM. Interestingly, TP53 is rarely mutated in at least two of these NF2associated cancers, mesothelioma or meningiomas (Murthy and Testa 1999;
Jaurand and Fleury-Feith 2005). Located on chromosome 22, NF2 may play a
role in maintaining normal cellular growth through many possible signal
transduction mechanisms, including CD44 and extracellular matrix, Rac-1
proteins, and MDM2. (Tsukita et al. 1994; Sainio et al. 1997; Sherman and
Gutmann 2001; Kim et al. 2004) The trend towards increasing MDM2 expression
as merlin expression decreases suggests that merlin may be involved in
regulation of MDM2 in mesothelial cells. To examine this possible relationship
more closely, we chose to re-express merlin in the H-meso-1 cell line, which
lacked merlin expression and had increased MDM2 expression.
Reintroduction of merlin into the H-meso-1 cell line resulted in both a
decreased growth rate as well as a decrease in saturation density, indicating
strict regulation of growth control. This is consistent with previous reports that
merlin is involved in contact inhibition of growth (Morrison et al. 2001).
Proliferation assays confirmed these merlin-induced changes in the cell cycle,
with significant decreases in BrDU uptake at all time points examined. The
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decrease in proliferation at high cellular densities, coupled with the decrease in
growth rate were verified by DNA content analysis suggesting G1-S-phase
transition had been altered in H-meso-1/NF2 cells. During HCD conditions when
merlin is activated, the percentage of H-meso-1/NF2 cells blocked in G1 phase
had increased significantly.
As NF2 is a tumor suppressor gene, alterations in cell cycle were not
entirely unexpected. Tumor suppressor genes may act at cell-cycle checkpoints
to prevent the clonal expansion of aberrant cells through the stimulation of
apoptosis, cell-cycle arrest, and DNA repair pathways. However, the increase
seen in p21 expression in H-meso-1/NF2 clones as compared to H-meso-1/CNT
clones suggest that merlin may be inducing this cell cycle arrest through a p53regulated pathway. The p21 protein is a member of the CDK family of cell cycle
inhibitors and an early cell cycle arrest response molecule (Toledo and Wahl
2006). Abnormalities in the expression of proteins from the CDK inhibitor family,
such as p21, have also been described in MPM (Kumar and Kratzke 2005). Hmeso-1/NF2 clones showed an increase in p21 expression at HCD as compared
to control cells. Although no response in apoptosis was detected in these cells in
response to camptothecin or UV exposures, an increase in Bax expression was
found in H-meso-1/NF2 cells as compared to H-meso-1/CNT cells. This
suggested that p53 function may be increased in H-meso-1 cells after merlin
expression and/or activation. This alone may be insufficient to return control to
the tumor cell line to allow apoptosis to take place. Multiple tumor suppressor
genes are inactivated in mesothelioma, and these experiments involve the
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replacement of only one. This renewal of p53 activity correlates with phenotypic
changes seen in proliferation, growth curves, and DNA content analysis and is
suggestive of a more “nonmalignant” or less transformed cellular phenotype.
In addition to alterations in p53-related cell cycle checkpoints altered, we
also found alterations in cyclin D1 expression. Increases in cyclin D1 expression
have been implicated in a number of cancers, including mantle cell lymphoma,
breast cancer, uveal melanoma, and ovarian cancer (Bartkova et al. 1995;
Coupland et al. 2000; Bali et al. 2004). Cyclin D1 is a critical cell cycle regulator
of the G1-S-phase transition, responsible for the phosphorylation of RB allowing
cells to transition into S phase (Knudsen et al. 2006). The evidence that merlin is
upstream of Cyclin D1 and plays a role in inhibition of its activity suggests that
NF2, much like the tumor suppressor gene p16/Ink4a, may also be upstream of
RB.
Discovered in 1993, NF2 research has increased our knowledge that this
tumor suppressor gene is a critical cell cycle regulator, responding to
extracellular cues and relating signals to downstream pathways (Trofatter et al.
1993; Tsukita et al. 1994; Sherman et al. 1997; Morrison et al. 2001). As
conventional cancer therapies such as radiation treatments, surgery, and
chemotherapy have not significantly lengthened the survival time of patients with
MPM, it is necessary to understand the molecular interactions that are altered in
order to improve patient treatment paradigms (Rusch 1995; Ryan et al. 1998).
Continued research of the intricacies involved in both cell cycle control and the
regulation of p53 and RB pathways would aid in the search for better patient care
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and earlier diagnosis in not only MPM but other cancer syndromes with similar
genetic profiles.
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Methods

Cell Culture and Transfections
All mesothelioma cell lines were maintained in RPMI media supplemented with
10% fetal calf serum, L-glutamine, and penicillin streptomycin. The MeT5a cell
line was grown in Medium199 with Earle's BSS, 0.75 mM L-glutamine and 1.25
g/L sodium bicarbonate supplemented with 3.3 nM epidermal growth factor
(EGF), 400 nM hydrocortisone, 870 nM insulin, 10% fetal calf serum, penicillin
streptomycin, sodium pyruvate, and non-essential amino acids.
Following transfection with pTRex vectors (Invitrogen, Carlsbad, CA), stably
transfected H-meso-1 clones had G418 (Invitrogen, Carlsbad, CA) added to the
above media to maintain transformation of cells. Prior to transfection with the
pTRex vectors, the H-meso-1 cell line had been transduced with the Tetrepressor pLenti6/TR vector (Invitrogen, Carlsbad, CA) and were maintained
under stable selection for using blasticidin (Sigma-Aldrich, St Louis, MO). This
was done to allow for controlled gene expression of merlin with the addtion of
doxycycline (Sigma-Aldrich, St Louis, MO) the media as a preemptive event in
case merlin reintroduction would not allow clones to grow. However, this Tetrepressor vector did not function properly and was not necessary as merlin
expression was achieved without doxycyline addition to the media.
H28, MeT5a, and H2052 were purchased from ATCC, H-meso-1 was purchased
from the NCI–Frederick Cancer DCTD tumor/cell line repository and was
previously characterized (Reale et al. 1987).
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Growth Curves
Cells were plated into 12 well plates at 10,000 cells per well. Cells were covered
with 2 mL of media and incubated at 37°C. Media was changed every 3 days.
At each time point, cells were counted in triplicate (3 wells of cells per count)
using a hemacytometer.
DNA Content
For low cell density (LCD) and high cell density (HCD) experiments, cells were
plated into 10 cm dishes at 300,000 cells/well for LCD and 1*106 cells/well for
HCD samples. Cells were incubated over night at 37°C.
Plates were washed with 5 ml of phosphate buffered saline (PBS), and treated
with 2 ml of trypsin for 2-5 minutes at 37°C. After cells had lifted off the plate, 5
ml of PBS was added and cells were carefully harvested and then transferred to
a 15 ml conical tube. Cells were centrifuged at 200*g for 6 min at room
temperature (RT), followed by two washes with PBS, centrifuging between
washes at 200*g for 6 min. Cells were resuspended in 500 µl of PBS, and fixed
by adding 4.5 ml of ice cold 70% ethanol dropwise while gently vortexing.
Samples were stored at -20°C at least 24 hours. Ethanol fixed samples were
centrifuged at 200*g for 6 min at RT, followed by two washes with 5 ml PBS.
Pellets were resuspended in 250 µl of propidium iodide/Triton-X 100 solution
(0.1% (v/v) Triton X-100 in 5 ml PBS, DNAse-free RNAse A (0.2 mg/ml) (Sigma
Aldrich, St. Louis, MO) and Propidium Iodide (0.02 mg/ml) (Sigma Aldrich, St.
Louis, MO). Samples were incubated for 30 min. at RT, and then analyzed on a
BD FACSCalibur. Fluorescence was read in the FL2 channel, which has a
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585/402 nm filter, set and cells were excited with a 488 nm laser. Data was
acquired with CellQuest version 3.3 and analyzed with ModFit version 3.1.
ImmunoBlots
Protein harvested from mesothelial cell lines was done by Dr. Melisa Bunderson
Schelvan. Dr. Schelvan was also responsible for the contribution of data
collected in the p53 and MDM4 Western Blot (Figure 14a). Cells were plated at
90,000 cells/well into 6 well plates for LCD and 300,000 cells/well for HCD and
incubated 24 hours. At time of protein harvest, LCD samples were ~60%
confluent for LCD and HCD samples were >90%. At the time of protein harvest,
media was removed and cells were washed with PBS. Cells were harvested in a
PBS-TDS lysis buffer (0.1% Triton X-100; 12.6 mM Sodium deoxycholate; 3.7
mM SDS; 1 mM EDTA; and 0.2 mM PMSF containing phosphatase and protease
inhibitors (Sigma Alrdich, St Louis, MO). Protein levels were measured using
the BioRad Protein DC assay (Bio-Rad, Hercules, CA). Samples were loaded
onto a 4-12% Bis-Tris Nupage gel (Invitrogen, Carlsbad, CA) then transferred
onto a PVDF membrane (Millipore, Bedford, MA). Membranes were blocked and
the primary antibody added. Following incubation with the primary antibody,
membranes were washed with PBS and Tween-20 (0.1% Tween-20) (PBS-t
(0.1%)), and a goat anti-mouse or goat anti-rabbit secondary antibody was
added. Membranes were washed with PBS-T (0.1%) prior to
chemiluminescence detection using the Immobilon Detection kit (Millipore,
Bedford, MA). Blots were stripped and reprobed for α-Tubulin as a loading
control. Antibodies used include: MDM2 (2A10), p21 (C-19), NF2 (A19), and
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p53 (DO-1) from Santa Cruz Biotechnology, Santa Cruz, CA; Bax (AM32) from
Calbiochem, San Diego, CA; α-Tubulin and β-actin from Sigma-Aldrich, St Louis,
MO; and GAPDH from (Cell Signaling, Danvers, MA).
Bromodeoxyuridine (BrdU) Uptake Assay
Cell were seeded at a density of 10,000 cells/well in a 96-well plate and allowed
to attach overnight. BrdU labeling reagent was added and cells were allowed to
incubate for 3h, 12h, or 24h. The BrdU Cell Proliferation Assay was completed
following the manufacturers protocol (Calbiochem, San Diego, CA).
UV Exposure
For experiments utilizing UV exposure to induce DNA damage for protein
expression changes, cells were plated in 6 well culture dishes at 90,000
cells/well. The next day, media was removed and wells were covered with 500 µl
PBS. Cells were placed in a Stratagene Stratalinker 1800 with no plate covers
and then exposed to 5J/m2. Following exposure, PBS was removed and
replaced with media. Cells were incubated at 37°C for 3 hours, media was
removed, cells were washed with PBS, and protein was harvested in protein lysis
buffer as previously described.
For apoptosis UV exposures, media was removed from incubated cells and
replace with 100ul of PBS. After cells were placed in the Stratagene Stratalinker
1800, covers of plates were removed and plates were then exposed to 5J/m2.
PBS was removed and replaced with fresh, and the cells were incubated at 37°C
for 24 hours.
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Camptothecin Exposure
Camptothecin was prepared in DMSO at 20 mg/ml. For exposure, the prepared
solution was diluted into regular media to 6 ug/ml. At time of exposure, media
was removed from wells, cells were washed once with 100 µL of PBS, and 100
µL of camptothecin-media was added to the wells. Cells were incubated at 37°C
for 3 hours.
TiterTacs Apoptosis Assay
Cells were plated in triplicate in two 96 well plates (one plate for UV exposure,
one plate served as no exposure control) at 40,000 cells/well. 48 hours after
plating, cells were exposed to either UV or Camptothecin. TiterTacs (Trevigen,
Helgerman, CT) was used according to manufacturers protocol to assess DNA
fragmentation.
LDH Assay
Cells were plated in triplicate in two 96 well plates (one plate for UV exposure,
one plate served as no exposure control) at 40,000 cells/well. 48 hours after
plating, cells were exposed to either UV or Camptothecin. The LDH-Cytotoxicity
Assay Kit (BioVision, Mountain View, CA) was used according to manufacturers
protocol to assess cell death or cytotoxicity.
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CHAPTER 3

Intratracheal Injection of Asbestos in NF2+/- Mice Provides Insight into
Cancer Susceptibility

Abstract

The neurofibromatosis type 2 gene (Nf2) was discovered in 1993 and shown to
harbor inactivating mutations in representative tumors from neurofibromatosis 2
patients. Nf2 is implicated in the development of other tumor types, including
malignant mesotheliomas. These mesodermally derived, primarily pleural tumors
display loss of chromosome 22 as one of the most common cytogenetic
abnormalities. The role of Nf2 in maintaining normal cellular growth may be
through many possible signal transduction mechanisms, including CD44 and
extracellular matrix, Rac-1 proteins, and MDM2. Previous studies have been
shown that mice hemizygous for Nf2 display an increased susceptibility for
asbestos-induced peritoneal tumors. Thus, Nf2 may play a central role in growth
regulation in mesothelial cells.
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Introduction

Malignant mesothelioma is an aggressive tumor that forms from the
serous membranes lining the pleural, peritoneal, and pericardial cavities (Baser
et al. 2002; Dunitz 2002; Cugell and Kamp 2004; Robinson et al. 2005; Tan and
Treasure 2005; Yang et al. 2008). Mesothelioma tumor development is heavily
linked to prior exposure to the fibrous mineral, asbestos, accounting for about
80% of mesothelioma cases (Wagner et al. 1960; Tweedale 2002; Cugell and
Kamp 2004; Jaurand and Fleury-Feith 2005; Yang et al. 2008). The main route
for exposure to asbestos is through inhalation of the fibers. Due to this common
route of exposure, the pleural space surrounding the lungs is the most commonly
affected mesothelial cavity, with about 70% to 95% of individuals diagnosed with
the disease presenting with pleural mesothelioma (Hammar 2006; Bridda et al.
2007; Yang et al. 2008).
Investigations conducted by Fleury-Feith and colleagues (2005) showed
the susceptibility of Nf2 hemizygous mice to develop peritoneal mesotheliomas
following exposure to a total of 5 mg of crocidolite asbestos via intraperitoneal
injections. In their studies, mice were exposed on two different occasions, with a
lag time of 2-3 months between exposures, to asbestos. This study clearly
showed the role for Nf2 in peritoneal mesothelioma development. However, as
pleural mesothelioma is the predominant form of the tumor, an exposure method
to induce lung injury might serve as a better model for MPM research.
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In this study, a heterozygous Nf2 knockout mouse model was used to
closely follow the early events in tumor development. Mice heterozygous for the
Nf2 gene have been shown to be predisposed to the development of
mesothelioma, as only one allele remains to be inactivated. Nf2 is an autosomal
dominant TSG, thus by Knudson’s Two-Hit Hypothesis, inactivation of both
alleles is necessary for loss of merlin function (Knudson 1971). Nf2
homozygosity is embryonically lethal, with mice carrying this genotype dying
before initiation of gastrulation (McClatchey et al. 1997). For this study,
hemizygous Nf2 knockout mice were used, and cellular and gene expression
changes in the exposed lungs were monitored. The hypothesis of this in vivo
study is that mice lacking a full complement of Nf2 genes will develop tumors at
earlier ages and in a larger percentage of animals than in control animals.
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Results

Inhalation of asbestos fibers is considered the main route of human
exposure to the particles, which occurs when the fibers are disturbed and
become airborne (ATSDR ; Tweedale 2002). Those fibers that are not expelled
can become lodged in the lung, and can continue to cause irritation over time. To
best mimic this exposure route while still maintaining a controlled dose of
asbestos, intratracheal injections (IT) were performed on mice using PBS as a
vehicle. Both Nf2+/+ mice and Nf2+/- mice were instilled with 100 µg of either
crocidolite asbsestos or Libby 6 Mix amphibole asbestos. Crocidolite asbestos
was used for exposures as it is generally considered the most hazardous of the
amphibole fibers. Libby 6 mix amphibole is a mixture of six different samples
collected from the Libby, MT mine site (Bellamy and Gunter 2008). The latency
for MPM development is long (20 to 40 years). This means that even after
exposure has stopped, asbestos fibers that have become lodged in the lung
continue to irritate the lung, thus promoting disease over a long period of time.
Thus, to mimic this latency period, after IT injections mice were monitored for a
12 month period. Following euthanasia, gross anatomy was examined and lungs
were harvested for histological evaluation.
In the event that mice died before the chosen time point, or if mice needed
to be sacrificed early if illness was detected, necropsy was performed and tissue
was harvested for histology if possible. Of these necropsied mice, the most
common event was the occurrence of osteosarcoma formation. Osteosarcoma
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development was most commonly found to occur in the Nf2+/- mice and was
independent of exposure type. Many groups have found that Nf2+/- mice are
prone to the development of malignant tumors, in particular osteosarcoma, but
these occurences are not related to loss of NF2 function (McClatchey et al. 1998;
Fleury-Feith et al. 2003; McClatchey 2003; Altomare et al. 2005; Lecomte et al.
2005). Only one of the mice that died before the 12 month time point had been
reached was found to have an abnormal growth on its lung, which upon gross
anatomical evaluation resembled a localized, nodular mesothelioma (Figure 20).
This mouse had been exposed to Libby 6 Mix amphible asbestos and was Nf2+/-.
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FIGURE 20
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Figure 20. Gross anatomy of mouse lung from a heterozygous mouse
exposed to asbestos.

The arrow points to the nodular area, that could be in this case a localized
mesothelioma or pleural plaque, located on the right lung of the mouse. This
was a heterzygous Nf2 mouse exposed to Libby 6 mix amphibole asbestos. The
mouse was exposed on 5/31/07 and died on 12/10/07.
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Initially for mouse instillations, different groups of mice were instilled on
four different occasions throughout the instillation year. Following the preliminary
analysis of tissue from the first two 12 month instillation groups, we decided to
include a 15 month exposure group by extending the time point for some of the
mice. Changes in the structure of the lung were identified using H&E staining,
which allows cell type identification as well as incidences of cellular hyperplasia.
In general, the most common type of pathology identified in mouse lungs from
the 12 month group were multifocal areas of epithelial cell proliferation. The
areas of the lung where this pathology was most prevelent were focused around
bronchioles and small airways. These lesions were regarded as hyperplastic. In
addition to pre-neoplastic regions, there were fibrotic regions, as well as
perivascular and peribronchiolar aggragates of lymphocytes (Figure 21). A
portion of the slides from this group are still under evaluation by Dr. Donald
Gardner, a pathologist at Rocky Mountain Laboratories.
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FIGURE 21
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Figure 21. H&E stained sections of 12 month mouse lungs.

Images of slides stained with H&E from mice involved in 12 month exposure
study. PBS exposed mice from both wild type and heterozygous groups
represent lungs classified as normal. Images from 6 Mix Amphibole and
crocidolite group depict hyperplasia and thus abnormal lung morphology through
disease manifestation. Possible regions of fibrosis can be seen in the crocidolite
and 6 mix wild type exposed mice.
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Mice sacrificed following a 15 month exposure period appeared to have an
increase in gross anatomical lung abnormalities. Autopsies performed at the
sacrifice of the mice revealed both nodular and diffuse mesothelioma, as well as
possible mice with asbestosis (Figure 22). Again, lungs were processed for
histological analysis and stained with H&E to evaluate cellular alterations. As
time progressed to the 15 month group, the amount and extent of cell
hyperplasia seemed to increase. Various patterns of cell hyperplasia occured,
with the predominant form being epithelial cell hyperplasia forming around
bronchioles and airways. In addition, lesions of cell hyperplasia occured around
arterioles as well. The different types of hyperplastic lesions, i.e. surrounding
bronchioles or surrounding arterioles, were independent of exposure type,
however again crocidolite seemed to be the most potent inducer of cell
proliferation. Some of the stained sections were classified as neoplastic, with the
majority of these determined to be adenocarcinomas or bronchogenic
carcinomas. However, these regions were not termed mesothelioma tumors
based on H&E stains. Again, fibrotic regions and lymphocyte aggregates were
found in some tissue (Figure 23) (Gardner 2008). Dr. Gardner is currently
evaluating H&E slides for the 15 month group.
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FIGURE 22

a)

b)
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Figure 22. Gross anatomy from 15 month group.

A nodule located on the exterior surface of the left lung of the mouse, which
could be a pleural plaque or a localized mesothelioma tumor (22a). Gross
anatomical analysis depicting a diffuse mesothelioma on the right lung of a
crocidolite exposed mouse (22b).
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FIGURE 23
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Figure 23. H&E stained sections of 15 month mouse lungs.

Images of slides stained with H&E from mice involved in 15 month exposure
study. PBS exposed mice from both wild type and heterozygous groups
represent lungs classified as normal. Images from 6 Mix Amphibole and
crocidolite group depict hyperplasia and possible neoplastic regions in both wild
type and heterozygous mice.
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For statistical interpretation of these results, H&E stained sections from
each group of mice were sent to Dr. Donald Gardner, a pathologist at Rocky
Mountain Laboratories. Dr. Gardner is currently evaluating slides consisting of 6
mice per group for the 12 month exposure group (36 mice total) and 4 mice per
group for the 15 month exposure group (24 mice total). Dr. Gardner is blinded to
both mouse genotype and exposure type, and will categorize the slides based on
the degree of hyperplastic alterations. Until his results arrive, I have scored
these slides and graded them for cell hyperplasia. For my evalutation, I scored 3
mice per group per time point. Mice exposed to crocidolite appeared to have an
increased amount of cell hyperplasia as compared to PBS and Libby 6 Mix
Amphibole asbestos (Figure 24). In addition, as time progressed, the
hyperplasia became more severe indicated by increases in average scores for
each group. However, Nf2 genotype appeared to not have an effect on
susceptibility to cell transformation.
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FIGURE 24
a) 12 Month Scores for Hyperplasia of H&E Stained Slides

b) 15 Month Scores for Hyperplasia of H&E Stained Slides
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Figure 24. Graphical representation of mouse scores for hyperplasia.

Pathology scores from mice in 12 month group show a significant increase in the
amount of hyperplastic lesions in crocidolite exposed mice (24a). Similarly,
scores generated from mice in 15 month group showed a significant increase in
the amount of hyperplasia compared to PBS control mice, with the average
scores in this group higher than those seen in the 12 month group (24b).
All statistics were conducted using slides from three mice per group using Twoway ANOVA.
*p<0.05 and ***p<0.001
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It was necessary to verify merlin expression status in the areas of cellular
hyperplasia. Sections of lungs were dual-labeled with both merlin and p21
antibodies to determine protein expression changes, and these images are
paired with the adjacent H&E stained section (sections are 7µm apart) in order
to better visualize lung morphology. Merlin expression was detected in primarily
Clara cells, whereas p21 expression was detected primarily in the smooth
muscle cells lining airways and blood vessels (Figure 25a and 25b, respectively).
Merlin also labeled cells in the alveolar space, however it is unclear what this cell
type is. These cells appear more dense surrounding hyperplastic regions of the
lung, and may be Type II pneumocytes (Figure 25c).
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FIGURE 25
a)

b)

c)
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Figure 25. Cell types labeled by merlin and p21 antibodies.

Antibody labeling of merlin appears to be focused in epithelial cells lining the
airways. As the predominant cell type in this region in murine lungs is Clara
cells, it is likely that Clara cells are expressing merlin. p21 expression appears to
be labeling airway smooth muscle cells (25a) (Gardner 2008). p21 expression
also labeled smooth muscle cells lining blood vessels in the lung (25b). An
additional cell type appears to express merlin in the alveolar spaces of the lung,
which I believe may be Type II pneumocytes (25c).
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Merlin expression was absent in almost all areas of cell hyperplasia,
regardless of initial mouse genotype. However, complete examination of these
same tissues revealed that in a non-hyperplastic region of the lung, merlin
expression could be detected. Expression of p21 revealed a similar pattern.
However, p21 expression was occasionally detected in hyperplastic areas.Loss
of expression of both these cell cycle regulators in hyperplastic portions of the
tissues is consistent with a model of tumorigenesis due to inactivation of TSGs.
Loss seems to have contributed to uncontrolled cell growth and expression
appears to be indicative of cells that are still capable of cell cycle exit (i.e. normal
phenotype). Figure 26 and Figure 27 are images revealing differential protein
expression in the lungs of the treated mice after 12 months and 15 months,
respectively.
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FIGURE 26
a) NF2 +/- Mice
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b) NF2 +/- Mice
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c) NF2 +/+ Mice
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d) NF2 +/+ Mice
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Figure 26. Immunofluorescent labeling of 12 month mouse lungs.

Immunofluorescent labeling of mice exposed to PBS and Libby 6 Mix amphibole
shows merlin and p21 co-expression, with minimal p21 expression in the PBS
exposed mouse, in a normal region of the lungs of a heterozygous mouse (26a).
In contrast, a NF2+/- mouse exposed to crocidolite identifies decreased merlin
expression in airway tissue and no p21 expression in hyperplastic areas. These
images are from the same mouse section (26b). Analysis of wild-type lung tissue
showed decreases in both merlin expression and p21 expression in lung sections
of a mouse exposed to PBS. This was consistent across all three samples
analyzed (26c). Merlin and p21 expression were detected in the lungs of wild
type mice exposed to Libby 6 Mix amphibole (26c). In a hyperplastic region of a
crocidolite exposed wild type mouse, merlin and p21 expression was absent. In
the same tissue, moving toward an area where a fibrotic response seems to be
occuring but not hyperplasia, expression of merlin lining the airways was
detected. In this region, there was minimal p21 expression lining the airways,
however it was expressed in the smooth muscle cells lining the blood vessels of
this region of the lung (26d).
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FIGURE 27
a) NF2+/- Mice
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b) NF2+/- Mice
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c) NF2+/+ Mice
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d) NF2+/+ Mice
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Figure 27. Immunofluorescent labeling of 15 month mouse lungs..
Immunofluorescent labeling of mice exposed to PBS shows frequent merlin and
p21 co-expression in a normal region of the lungs of a heterozygous mouse
(27a). In a nodular region of a section from a NF2+/- mouse exposed to Libby 6
Mix amphibole, merlin and p21 expression were not detected. In this same
section, both merlin and p21 expression were detected around an airway with
normal morphology (27a). A NF2+/- mouse exposed to crocidolite (labeled as
CRO in figure 27b) identifies decreased merlin expression in a hyperplastic
region of an airway, but expression of p21. In this same section, in a region
where hyperplasia was not as abundant but a fibrotic response seems to be
occuring, both merlin and p21 expression were detected (27b). Images taken
from another NF2+/- mouse exposed to crocidolite (labeled as 27b CRO 2) show
no labeling of merlin or p21 in a neoplastic region of a lung. Images collected
further into the lung start to show p21 and merlin expression. Finally, in a
different lobe of the same CRO 2 lung with normal morphology, merlin was highly
expressed (27b CRO2 final image). Analysis of wild-type lung tissue showed coexpression of merlin and p21 in lung sections of a mouse exposed to PBS (27c).
p21 expression was not detected in the lungs of wild type mice exposed to Libby
6 Mix amphibole in a hyperplastic area, but merlin expression in this region
appeared to be labeling a cell type which has not been identified (27c). In a
fibrotic region of a crocidolite exposed wild type mouse, merlin and p21
expression were absent. In the same tissue, moving toward an area of more
normal lung morphology, both proteins were expressed (27d).
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Conclusions

Evidence for the importance of Nf2 as a TSG in mesothelioma is provided
by the occurrence of gene inactivation in the majority of tumor incidences (Sekido
et al. 1995; Baser et al. 2002; Carbone et al. 2002; Fleury-Feith et al. 2003;
Lecomte et al. 2005; Robinson et al. 2005; Musti et al. 2006). In vivo approaches
aimed at delineating this role have shown that NF2 heterozygosity contributes to
early mesothelioma development. Previous studies in vivo have primarily
focused on peritoneal mesothelioma development, which accounts for less than
10% of the already rare mesothelioma tumors (Fleury-Feith et al. 2003; Bridda et
al. 2007; Yang et al. 2008). In addition, large doses of asbestos have been used
to induce mesothelioma formation. Here, we were able to induce hyperplasia, as
well as neoplasia in some cases, in mouse lung cells using IT injections of just
100 µg of asbestos. Although further verification is necessary, it is possible that
some of the neoplastic formations were if fact pleural mesothelioma. Based on
the subjective and un-blinded lungs scores that were given to H&E stained lungs
on interpretation of lung hyperplasia, there appears to be no correlation with the
predisposition of missing one Nf2 allele to increased hyperplasia as compared to
wild type counterparts, as both genotypes of mice developed hyperplastic
regions of the lung. However, these results are subject to change upon the
arrival of hyperplastic scores from Dr. Gardner.
The cell types that merlin and p21 labeled were predominantly Clara cells
and smooth muscle cells, respectively. This will need to be verified by double
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staining with Clara cell specific markers (CC10) or smooth muscle specific
markers. In the terminal bronchioles the predominant cell type is the Clara cell,
and these cells represent the precursors to ciliated cells that also line these
airways. Merlin also appears to stain an additional cell type that is not
identifiable, but is most likely a Type II pneumocyte. Type II pneumocytes are
capable of undergoing cellular division and are progenitor cells for Type I cells.
Both of these cell types, like mesothelial cells, respond to injury to repair lung
tissue. In response to cell loss and injury, regenerative hyperplasia of both Type
II pneumocytes and airway epithelium occurs which may lead to neoplasia (Dixon
et al. 1999; Gardner 2008).
Protein expression of p21 appeared to label airway smooth muscle cells..
Airway smooth muscle cells have been regarded as contractile tissue,
responding to proinflammatory mediators and bronchodilators to regulate airway
size, surrounded by and reacting to the extracellular matrix (Howarth et al. 2004).
Thus, in response to cues generated by the extracellular matrix, these cells
respond to injury and are capable of proliferation and migration if necessary
(Gounni et al. 2005). Expression of p21 was detected in both normal and
hyperplastic regions of the lungs, indicating that this cell cycle checkpoint has
been activated. More importantly, p21 expression was also absent in some
hyperplastic regions, which could be indicative of loss of function of p53, and this
absence of expression often correlated with regions where merlin was not
detected. Whether these events are related has not been determined.
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The majority of asbestos exposures occur through occupational means,
including the mining of asbestos, the mining of asbestos-contaminated products
(e.g. vermiculite or talc), or through the manufacturing of such materials. In
addition, family members of those involved in such occupations can be exposed
to asbestos as the particles can be brought home on one‘s clothing when the
particles become aerosilized and spread throughout the environment. As many
asbestos containing materials are present in our everyday environment, such as
in insulation, floor tiles, roofing, etc., many people have the potential to be
exposed to this hazardous material (ATSDR). Crocidolite is long regarded as the
most potent of the amphibole fibers in regards to ARDs, and here we have
shown that these fibers used in this study were capable of hyperplastic
transformation after a 12 month exposure to the fibers, as well neoplastic
transformation after 15 month exposure.
Vermiculite, a product largely used for fireproofing, soil amendments, and
insulation, was mined from the Zonolite Mountain located near Libby, MT
(Meeker et al. 2003). The mine was in operations from the 1920s until 1990 and
was at one time the world’s largest source of vermiculite, producing 80% of the
world's supply (Bandli and Gunter 2006). As early as 1959, the vermiculite was
found to be contaminated with asbestos and was causing disease manifestation
in workers, however the mine continued to operate until the 1990 mine closure
(Meeker et al. 2003; Bandli and Gunter 2006). Since 1995, 44 cases of
mesothelioma have been identified resulting from exposure to asbestos
contamination in Libby, MT (Whitehouse et al. 2008).
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In this study, Libby 6 Mix amphibole asbestos did not appear to have an
impact on the induction cell hyperplasia as compared to PBS exposed mice.
This is likely due to Libby 6 Mix amphibole fibers that were available for use at
the time of mouse exposures. At the time that these exposures were performed,
the fibre type that was available for use consisted of a mixture of fiber sizes.
However this fraction size does not represent a respirable fraction that could
cause disease. Since this time, an elutriated version of these fibers have
become availble, allowing for an exposure sample more representative of the
fiber type capable of causing disease. Repetition of this portion of the study
using these elutriated fibers is necessary to draw conclusions on the impact that
these fibers might have on mesothelioma development.
Although the degree and time to cell hyperplasia were not dependent on
the predisposition of Nf2 heterozogosity, almost all regions of where hyperplasia
occured had lost merlin expression, suggesting that inactivation Nf2 is a
necessary step in the cellular transformation following asbestos exposure.
Where merlin expression was not detected, loss of function appears to have
contributed to cell hyperplasia. This confirmed the importance of Nf2 in the
maintenance of normal cell growth. In addition, p21 expression was absent in
some areas of mild to moderate cell hyperplasia, but was absent in most
neoplastic regions. Because these proteins appear not to be expressed in the
same cell type, it is difficult to determine whether or not these alterations in
expression were related events.
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MPM is relatively untreatable, with a survival time post-diagnosis less than
2 years. As with any cancer, understanding the molecular mechanisms that are
altered will help with the design of more effective treatment strategies. This
becomes especially important for MPM patients, because of the poor response
that this disease has to current therapies. A mouse model is a useful tool for
understanding the biological changes that take place leading to tumor formation
following asbestos exposure (Meuwissen and Berns 2005). Eventually, the
molecular and cellular events that take place during this process can be
dissected, allowing for the development of earlier diagnostic tools and treatment
strategies.
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Methods

Mouse Genotyping
C57BL/6/129S Nf2+/- mice were a kind gift from Dr. Joseph Kissil from the Wistar
Institute in Philadelphia, PA. DNA was isolated from tail snips from the mice
using DNeasy Blood and Tissue Kit (Qiagen ,Valencia, California) according to
the manufacturers protocol. DNA was genotyped according to methods
described by McClatchey et al. (1998). Basically, three primers (primer a: 5’GGGGCTTCGGGAAACCTGG-3’; primer b: 5’-GTCTGGGAAGTCTGTGGAGG3’; and primer c: 5’-CTATCAGGACATAGCGTTGG-3’ were used for PCR
amplification, producing two products. Primer pair a and b amplifies a 306-bp
product from the wild-type allele, whereas primer pair a and c amplifies a 575-bp
product from the mutant allele.
Asbestos Preparation
Mice will be exposed to two forms of asbestos particles, Libby Amphibole from
U.S. Geological Survey and crocidolite from Research Triangle Institute (RTP,
NC). Fibers were weighed out and suspended in PBS to a final concentration of
33.3 mg/mL. Solutions were sonicated to ensure particle suspension. As a
negative control of the disease, mice (both knockout and wild type) will be
exposed to sterile saline (30 uL/mouse) using the same IT procedure as
described for the asbestos exposed groups.
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Intratracheal Instillation
Nf2+/- and Nf2+/+ mice were exposed to a dose of 3mg/mL (30 uL/mouse)
asbestos via intratracheal (IT) instillation. The animals were anesthetized with
100µL of a ketamine (80mg/kg) and xylazine (12mg/kg) cocktail IP using a 23-25
gauge needle. The anesthesia lasts about 10-15 minutes, at which point a small
incision was made into the neck (about 4-8mm). After opening the skin, the
trachea was exposed and 30 µl of the above mentioned asbestos or sterile PBS
was injected directly into the trachea. The skin was then closed with sterile
tissue glue and the area was treated with betadine to help prevent infection. The
animals were warmed on a heating pad, and usually were back to normal activity
after about 1 hour.
Mice were monitored for signs of distress, which include cachexia, dypsnea,
increase in chest wall mass, or cyanosis (nose and tail). If any of these signs of
distress were detected, the mice were euthanized through IP injection of an
overdose of 50 mg/kg pentol barbital.
Lung Fixation and Processing
Lungs were harvested from mice following euthanasia described above.
Immediately following the removal of the lungs and hearts from the body cavity of
the mouse, the lungs were perfused with about 200 µL of Histochoice (Amresco,
Solon, Ohio), and then placed in a 15 mL conical tube with 7 mL Histochoice.
Tubes were stored at 4°C at least 24 hours before processing of tissue, not to
exceed 48 hours in Histochoice fixative. Lungs were processed in a Shandon
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Citadel auto-processor using the following program: 30 min in 70% ethanol
(EtOH), 30 min in 95% EtOH, 2 changes 1 hour each in 100% EtOH, 2 changes
of 1 hour each in methyl salicylate, 45 min in paraffin, and finished in 1.5hr in a
2nd paraffin wax. Lungs were sliced in 7µm thick sections.
Hematoxylin and Eosin Stain (H&E)
For H&E staining, slides were stained in a Shandon Varistain 24-4 auto-stainer
using the following program: 3*5 min in xylene, 2*3 min in 100% EtOH, 3 min in
95% EtOH, 3 min in 70% EtOH, 5 min in deionized water (dH2O), 5 min in Harris
Hematoxylin, 5 min in dH2O, 30 sec in acid alcohol, 5 min in dH2O, 1 min in
bluing, 5 min in 70% EtOH, 2 min in eoxin, 5 min in 95% EtOH, 2*5 min in 100%
EtOH, and 3*5min in xylene.
Immunohistochemistry
Sections mounted on slides were rehydrated by incubating 3*5 minutes in xylene,
followed by 2*3 min incubation in 100% EtOH, a 3 min incubation in 95% EtOH, a
3 min incubation in 70% EtOH, and finished with a 5 min wash in PBS.
Slides were boiled in Citric Acid Buffer (10mM Citric Acid, pH6, with 0.1% Tween
20) for 10 minutes. After 10 minutes, the solution was removed from heat and
allowed to sit in the buffer for 10 minutes. The slides were placed in a PBS wash
for 5 minutes. Sections were circled with a hydrophobic pen, and blocked with
4% goat serum diluted in PAB buffer (PBS containing 2% BSA and 0.01%
sodium azide). Primary NF2 antibody (A19, Santa Cruz Biotechnology, Santa
Cruz, California) was diluted 1:50 in PAB and allowed to incubate overnight at
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4°C. The following day, slides were washed 2*5 min in PBS. Secondary
antibody (goat-anti-rabbit Alexa Fluor® 488) was added at 1:400 dilution in PAB
and allowed to incubate in the dark at room temperature for 1 hour. Slides were
washed 2*5 min in PBS. Primary pre-conjugated p21 Alexa Fluor® 647 antibody
(C19, Santa Cruz Biotechnology, Santa Cruz, California) was added at 1:10
dilution in PAB and allowed to incubate overnight at 4°C. The following day,
slides were washed 2*5 min in PBS followed by 3 quick rinses in dH2O before
coverslipping with Flurosave.
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DISCUSSION

Since its discovery, NF2 has been suggested to be a unique tumor
suppressor gene, mainly because of its subcellular localization and connection
with the cell membrane (Trofatter et al. 1993; Brault et al. 2001; McClatchey and
Giovannini 2005). Researchers have shown that this gene is involved in cellular
growth regulation through its involvement in contact inhibition of growth, cell
proliferation alterations, and apoptotic response. Here, we have shown that NF2
is not only involved in the relaying of signals involved in these pathways, but
activity of the gene may ultimately affect the function and/or activity of two key
TSGs, TP53 and RB.
This study has primarily focused on how NF2 inactivation might be
involved upstream in the regulation of p53, attributed to its possible involvement
in the degradation of MDM2. MDM2 helps to maintain low steady-state p53
levels through ubiquitination and subsequent proteasome degradation. We were
able to show that alterations in the protein level of merlin (the NF2 gene product)
resulted in inverse alterations in MDM2 protein levels. MDM2 protein level
changes also correlated with alterations in p53 activity. For example, in Chapter
1 we showed that suppression of merlin resulted in increased MDM2 protein and
subsequently decreased p21 and Bax expression, indicating p53 activity had
been negatively affected by merlin loss. It remains unclear whether merlin is
degrading MDM2 in this pathway or inhibiting its activity through other
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mechanisms. Future studies could assess the ubiquitination status of p53 and
could provide more information regarding MDM2 activity levels.
As the major TSGs RB and TP53 are commonly found mutated in other
cancers, how malignant mesothelioma tumors arise while still retaining these two
major TSG in their wild-type form is unclear. Alterations in the cell that might
contribute to loss of function of these genes need to be elucidated. In
mesothelioma, it seems plausible that both p53 and RB are not capable of
functioning properly, thus the hyperplastic cells do not require inactivation of the
p53 or RB to progress to neoplasms. The mechanisms for this malfunction of
both RB and p53 has largely been attributed to p16 and p14, respectively. Here
we have shown that merlin not only contributes to loss of p53 activity, but via
mechanisms such as Cyclin D1, it may also contribute to Rb loss of function as
well (Figure 28). We were able to confirm a role for merlin in the regulation of
Cyclin D1, which is involved in the progression from G1 to S phase of the cell
cycle. One of the means by which Cyclin D1 initiates this transition is via
phosphorylation of Rb. Investigations aimed at the phosphorylation status of Rb
following merlin expression level alterations might provide insight into this
pathway.
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FIGURE 28
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Figure 28. A possible mechanism for NF2 in the control of the activity of
p53 and RB.

Merlin, the protein product of NF2, may act upstream of p53 to regulate activity of
the TSG by negatively regulating MDM2. Similarly, merlin may act upstream of
Rb by inhibiting Cyclin D1. When NF2 is inactivated, in combination with the
inactivation other genes like p16 and p14, an increase in inhibition of p53 and Rb
can occur resulting in continual transition into S phase and thus loss of cell cycle
control.
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Using a mouse model to recapitulate genetic alterations that occur in
humans following asbestos exposure, we were able to demonstrate the toxicity of
asbestos in terms the carcinogenic potential of the fibers. While cell hyperplasia
occurred in many of the asbestos-exposed mice, the majority of these cases
were not termed mesothelioma by the pathologist. Further analysis of these
samples using histological markers to verify the type of tumor formation may
provide more information into the tumor types seen. Instead, as this study could
be considered a pilot study of mesothelioma development using an IT exposure
route, it might be useful to repeat this study including an additional exposure time
point. Such an approach would be more similar to human exposure to asbestos,
as most asbestos exposures are not likely one-time occurrences, but occur over
a period of time. Another advantage to repeating this portion would be the
inclusion of additional time points, both shorter and longer, in an attempt to
determine the time of NF2 inactivation and possible information on earlier
diagnosis. Once a consistent in vivo approach for the development of
mesothelioma is achieved, this model could be used in the testing of
therapeutics, possible testing gene therapy targeting mesothelial cells expressing
NF2.
Genetic variance among patients involved in Phase I clinical trials, which
typically include about 30 people, usually results in at least one death due toxicity
of the drug being tested (Ames 2008). This is primarily due to genetic variability
in genes responsible metabolism of the drugs being administered, but it can also
be applied to gene alterations that occur in the cancer tissue. Genotyping of
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individuals prior to treatment will be a critical step for improving clinical outcomes.
In the case of mesothelioma, genotyping can be further focused to commonly
inactivated genes for targeted gene therapy approaches. There is genetic testing
available for NF2, including both mutation analysis and linkage analysis, for NF2
patients (Yohay 2006). As this tool is available, gene therapy could be used to
specifically target those tumors where NF2 is inactivated to re-express the gene
with the hopes of slowing tumor growth. In addition, in mesothelioma patients
that retain wild-type NF2, it may be that overexpression of NF2 will be useful. Of
the possible uses for NF2-targeted gene therapy, one that involves a
combination of this approach with other therapeutic options will likely be the most
effective treatment to benefit patients. Jongsma et al. (2008) found that codeletion of NF2 along with the INK4a locus in mice without asbestos exposure
was sufficient to induce mesothelioma, highlighting the importance of these
genes in tumor development. In particular, combination gene therapeutic options
that include both the INK4a locus, which houses the TSGs p14 and p16, and
NF2 may have promising results, where these genes could stabilize p53 and Rb
resulting in the restoration of cell-cycle checkpoints and tumor suppression.
This study has provided useful information regarding the tumor suppressor
capabilities of the TSG, NF2. The potential for NF2 to act upstream of p53 adds
to the importance of retention of this gene in the maintenance of normal cellcycle control. Research investigating the role of NF2 in other cancers will further
our knowledge on the tumor suppressor capabilities of not only NF2, but also the
regulatory mechanisms of p53 and possibly Rb.
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APPENDIX A

Vector Maps Used in Chapters 1 and 2

Gene Expression Array Relevant to Chapter 1
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Figure 29. Vector map of plasmid used in Chapter 1.
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Figure 30. Vector map of control plasmid used in Chapter 1.
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Figure 31. Vector map of plasmid used in Chapter 2.
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Figure 32. Vector map of control plasmid used in Chapter 2.
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Figure 33. Vector map of Tet-Repressor plasmid used in Chapter 2.
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A microarray was performed on MeT5a clones generated in Chapter 1 to
understand some of the gene expression changes that take place following NF2
suppression. Two Nf2-suppressed clones generated from two different NF2shRNA targets (9973-6 and 9974-5) were used for this analysis and compared to
MeT5a-CNT9 cells. The resulting upregulated and down regulated gene
expression changes that were shared between the two clones are listed in Table
3 and Table 4, respectively.
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Table 3. Genes upregulated in MeT5a clones following NF2-suppression.
Gene
Symbol

Gene Name

Biological Processes

Cellular
Component

Fold
Change

p-value

EMP3

Epithelial membrane protein 3

Cell growth

Integral to
membrane

1.76

0.021

PRDX6

Peroxiredoxin 6

Cell redox homeostasis

nucleus, cytoplasm,
lysosome

1.77

0.039

FPRL1

Formyl peptide receptor-like 1

Inflammatory response, cell
adhesion, signaling pathways

Integral to
membrane

1.55

0.022

CLCA4

Chloride channel, calcium activated, family
member 4

Transport

Extracellular region,
integral to
membrane

1.83

0.023

KCNMB4

Potassium large conductance calciumactivated channel, subfamily M, beta
member 4

Ion Transport

Membrane

1.75

0.013

SDHC

Succinate dehydrogenase complex, subunit
C, integral membrane protein, 15kDa

Transport

Integral to
membrane

1.57

0.022

SLC11A2

Solute carrier family 11 (proton-coupled
divalent metal ion transporters), member 2

Transport

integral to
membrane

1.65

0.020

GJA4

Gap junction protein, alpha 4, 37kDa
(connexin 37)

Cell Communication, CellCell Junction Assembly,
Transport

Integral to
membrane

1.63

0.009

EIF4A1

Eukaryotic translation initiation factor 4A,
isoform 1

Translation

Cytosol

1.55

0.023

GDF3

Growth differentiation factor 3

Growth factor activity

Extracellular region

1.73

0.020

HTR2C

5-hydroxytryptamine (serotonin) receptor 2C

Signaling pathway

Integral to
membrane,
cytoplasm

1.64

0.016

PDLIM5

PDZ and LIM domain 5

Actin Binding

Cytosol, actin
cytoskeleton

1.66

0.008

NFIX

Nuclear factor I/X (CCAAT-binding
transcription factor)

DNA replication

Nucleus,
intracellular

1.74

0.009

CALB1

Calbindin 1, 28kDa

Locomotory behavior

Cytosol, nucleus

1.52

0.018

ITGAV

Integrin, alpha V (vitronectin receptor, alpha
polypeptide, antigen CD51)

Cell adhesion, integrinmediated signaling

Cytoplasm, plasma
membrane

1.84

0.037
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Table 4. Genes down regulated in MeT5a clones following NF2
suppression.

Gene
Symbol

Gene Name

Biological Processes

Cellular Component

Fold
Change

p-value

ASPN

Asporin (LRR class 1)

Protein binding

Membrane

-4.68

0.005

TMEM104

Transmembrane protein 104

Not Found

Integral to membrane

-4.49

0.017

CABIN1

Calcineurin binding protein 1

Cell surface receptor linked
signal transduction

Nucleus

-4.16

0.025

AARS

Alanyl-tRNA synthetase

Translation

Cytoplasm

-3.40

0.006

LCN1

Lipocalin 1 (tear prealbumin)

Transport

Extracellular region

-3.23

0.022

GABRE

Gamma-aminobutyric acid (GABA) A
receptor, epsilon

Ion Transport

Integral to membrane,
Cell junction

-2.51

0.027

PC

Pyruvate carboxylase

Metabolic Process

Mitochondrion

-2.25

0.036

NCF1

Neutrophil cytosolic factor 1

Cell communication

Cytoplasm

-2.21

0.016

TLOC1

Translocation protein 1

Intracellular protein
transmembrane transport

Integral to membrane

-2.21

0.020

TMSB10

Thymosin, beta 10

Actin cytoskeleton organization

Cytoplasm

-1.93

0.016

ENO1

Enolase 1, (alpha)

Negative regulation of cell
growth

Cytoplasm

-1.69

0.006
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Methods

RNA Isolation
Total RNA was isolated from cell lines using the standard Trizol Reagent
(Invitrogen, Carlsbad, CA) according to manufacturer’s protocol. A further RNA
cleanup step was performed using an RNeasy (Qiagen, Valencia, CA) to remove
contaminants. RNA quantity and quality were assessed using a Nanodrop
Spectrophotometer (Nanodrop Technologies, Wilmington, DE) and Agilent
Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Microarray Analysis
Gene expression changes following suppression of NF2 were assessed for
MeT5A 9973-6 and MeT5A 9974-5 cell lines compared to MeT5A control-9 cells.
Reverse transcription and cDNA labeling were performed using 8 µg of total RNA
according to the Superscript Plus Direct cDNA Labeling Kit (Invitrogen). Labeling
efficiency was determined using a Nanodrop Spectrophotometer (Nanodrop).
Labeled cDNA was hybridized overnight at 42°C to in-house spotted arrays of
oligonucleotides produced by MWG Biotech, Inc. (High Park, NC). Arrays were
scanned and analyzed using an Axon GenePix 4000B microarray scanner and
Axon GenePix Pro 5.1 software (Molecular Devices, Sunnyvale, CA) . Further
analyses were performed using Iobion GeneTraffic Duo (Stratagene, La Jolla,
CA), GoMiner (NCBI), and PathwayStudio (Ariadne Genomics, Rockville, MD).
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